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Abstract 
 
Type 1 diabetes (T1D) is an autoimmune disorder, where autoreactive cells are directed towards 
beta cells of the pancreas that produce insulin. This islet destruction and the chronic inflammation 
is facilitated by various immune cells specifically, macrophages, dendritic cells and T 
lymphocytes. We have previously shown that a dysfunction in the Treg pool and their 
suppressive function in NOD mice could be restored by GM-CSF or TSLP administration, which 
are recognized to activate the STAT5 signaling pathway. Since STAT5B dysfunction has 
emerged as a contributor to DC abnormalities that may contribute to Treg defect in T1D in NOD 
mice, we generated NOD.CD11c.STAT5B-CA transgenic mice expressing a constitutively 
active form of the STAT5B gene under the control of CD11c promoter. We observed that 100% 
of NOD.CD11c.STAT5B-CA transgenic mice were protected from disease, and protection was 
associated with an increased pool and suppressive function of Tregs. These data suggest that 
Treg development in STAT5B-CA.DCs environment leads to stable Tregs that are key cells in 
maintaining immune tolerance in NOD mice. Consistent with these findings, antigen-specific 
Tregs differentiated in vitro, in the presence of STAT5B-CA.DCs exhibited high suppressive 
function. Similarly, purified nTreg from NOD.CD11c.STAT5B-CA mice displayed high 
suppressive function compared nTregs purified from NOD mice. nTregs of 
NOD.CD11c.STAT5B-CA mice express high levels of suppressive inhibitory markers such as 
CTLA-4 when compared to nTregs of NOD mice. Checkpoint inhibitory molecules play a crucial 
role in optimal Treg suppression of autoreactive cells. Interestingly, NOD.CD11c.STAT5B-
CA.LAG-3-/- mice become diabetic and have a drastic reduction of Tregs compared to 
NOD.CD11c.STAT5B-CA mice. These results suggest that Treg stability was restored in 
STAT5B-CA.DCs environment but lost in the absence of LAG-3. PD-1, CTLA-4 and LAG-3 
checkpoint inhibitory molecules expressed on Tregs of NOD.CD11c.STAT5B-CA mice 
compared to pre-diabetic NOD and NOD.CD11c.STAT5B-CA.LAG-3-/- mice was 
characterized to provide an idea as to which may be more important in protection against disease. 
Interestingly, CTLA-4 was upregulated only on Tregs in NOD.CD11c.STAT5B-CA mice but 
not on Tregs of NOD and NOD.CD11c.STAT5B-CA.LAG-3-/- mice. Moreover, PD-1 and 
LAG-3 molecules were found to be upregulated only on non-Tregs (CD4+ T-cells) of 
NOD.CD11c.STAT5B-CA mice compared to NOD mice. These results suggest that CTLA-4 
may be important for Treg mediated suppression of NOD.CD11c.STAT5B-CA mice, whereas 
PD-1 and LAG-3 expression may be important for certain CD4+ T-cell subsets in suppression of 
autoimmunity. 
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Résumé 
 
Le diabète de type 1 (DT1) est une maladie auto-immune, dans laquelle les cellules autoréactives 
sont dirigées vers les cellules bêta du pancréas qui produisent de l'insuline. Cette inflammation 
chronique du pancréas et la destruction des îlots sont facilitées par diverses cellules immunitaires, 
notamment les macrophages, les cellules dendritiques et les lymphocytes T. Nous avions 
précédemment montré qu'un dysfonctionnement du pool et de la fonction suppressive des Tregs 
chez les souris NOD pourraient être rétablis par l'administration de GM-CSF ou de la TSLP, qui 
sont reconnues pour activer la voie de signalisation STAT5. Puisque le dysfonctionnement de 
STAT5B est devenu un facteur contributif des anomalies des cellules dendritiques (DC) pouvant 
contribuer à un défaut de Tregs chez les souris NOD, nous avons généré des souris transgéniques 
NOD.CD11cSTAT5B-CA exprimant une forme constitutivement active du gène STAT5B sous 
le contrôle du promoteur CD11c. Nous avons observé que 100% des souris transgéniques 
NOD.CD11cSTAT5B-CA étaient protégées contre la maladie et que cette protection était 
associée à une augmentation du pool et de la fonction suppressive des Tregs. Ces données 
suggèrent que le développement de Tregs en présence de STAT5B-CA.DC a conduit à des Treg 
stables qui jouent un rôle important dans le maintenance de la tolérance immunitaire chez les 
souris NOD. Conformément à ces découvertes, la différenciation in vitro des Tregs, spécifiques 
à un antigène du soi, en présence de STAT5B-CA.DCs, présentaient une fonction suppressive 
élevée. De façon similaire, les nTreg purifiés des souris NOD.CD11cSTAT5B-CA ont présenté 
une fonction suppressive élevée par rapport aux nTreg purifiés des souris NOD. Les nTregs des 
souris NOD.CD11cSTAT5B-CA expriment des niveaux élevés de marqueurs inhibiteurs tels que 
CTLA-4 par rapport aux nTregs des souris NOD. Les molécules inhibitrices du Tregs jouent un 
rôle crucial dans la suppression optimale des cellules autoréactives. Fait intéressant, 50% des 
souris NOD.CD11c.STAT5B-CA.LAG-3-/- deviennent diabétiques et présentent une réduction 
drastique des Tregs par rapport aux souris NOD.CD11cSTAT5B-CA. Ces résultats suggèrent 
que la stabilité des Tregs a été restaurée dans l'environnement STAT5B-CA.DCs mais perdue en 
l'absence de LAG-3. Les molécules inhibitrices PD-1, CTLA-4 et LAG-3 exprimées sur les Tregs 
et non Tregs des souris NOD.CD11cSTAT5B-CA ont été comparées aux souris pré-diabétiques 
NOD et NOD.CD11cSTAT5B-CA.LAG-3-/-. De façon intéressante, CTLA-4 est augmenté 
seulement chez les Tregs des souris NOD.CD11cSTAT5B-CA mais pas chez les Tregs des souris 
NOD.CD11cSTAT5B-CA.LAG-3-/-. De plus, PD-1 and LAG-3 sont régulés à la hausse 
seulement chez les cellules non-Tregs (CD4+ T cells) des souris NOD.CD11cSTAT5B-CA 
comparativement aux souris NOD. Nos résultats suggèrent que CTLA-4 serait important pour la 
fonction suppressive des Tregs des souris NOD.CD11cSTAT5B-CA alors que l’expression de 
PD-1 et LAG-3 par certaines populations de cellules T CD4+ seraient importants pour participer 
au contrôle des réactions autoimmunes. 
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1. Introduction 
 
 
 
Type 1 diabetes (insulin-dependent) is a multifactorial autoimmune disorder 
characterized by pancreatic beta cell destruction, resulting in complete insulin deficiency. 
Type 2 diabetes (non-insulin dependent), on the other hand, is characterized by both 
resistance to insulin and failure in compensatory insulin secretion by the pancreas (Maahs et 
al. 2010). Although type 2 diabetic patients can go years without noticing any symptoms, 
type 1 diabetic patients may display symptoms suddenly and without warning. However, 
there is overlap between some of the symptoms of the two types of diabetes. Early common 
symptoms include hyperglycemia, polyuria, excessive thirst, weight gain or loss (more 
common in type 1 diabetes), blurry vision, fatigue and a tingling feeling of the extremities 
(Ramachandran 2014). 
 
 
The most commonly used treatment regimen for type 1 diabetes includes combining 
strict diet and exogenous insulin administration (Pathak et al. 2019). Although various insulin 
delivery devices are in use, recurring episodes of hypoglycemia remains a challenge for 
patients and health care providers. Therefore, the use of continuous glucose sensors and 
infusion systems have become more popular. Additionally, this has paved way for the 
development of the artificial pancreas, also referred to as “closed-loop system”, that 
continuously screens blood glucose levels and injects only the needed amount of insulin 
(Pathak et al. 2019). This allows for improved blood glucose control resulting in reduced 
insulin spikes and hypoglycemia episodes. However, drawbacks of the closed loop system 
remain yet a challenge - including inconsistencies in outcome reporting, high costs, increased 
scar tissue caused by repeated microneedle injections and early sensor malfunction. Islet cell 
transplantation has also considerably improved in efficacy over the past 2 years, yet there are 
limitations including hazardous consequences of immunosuppressive drugs, islet cell 
apoptosis and ischemia that result in islet cell loss. Various immunotherapies have also been 
underway since the 1980s, yet repeatedly failed in clinical trials highlighting the urgency for 
improved immune therapies to treat patients successfully (Pathak et al. 2019). 
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1.1 Prevalence 
 
Of the two major types of diabetes, type 1 accounts for 5-10% of the total cases. It 
accounts for the majority of cases seen in youths worldwide (Maahs et al. 2010). In a sample 
study of Canadian youth, the highest incidence age was observed in children aged 5 - 14 
years where the most significant peak in incidence was between 10 - 14 years old (Fox et al. 
2018). Epidemiological statistics reported Canadians diagnosed with T1D have been living 
with the disease for an average of 20.2 years, whereas type 2 averaged 12.2 years (Statistics 
Canada. Health Statistics Division 2017). In Canada, approximately 33,000 children between 
5 - 18 years of age have type 1 diabetes, and several thousand younger than 5 years of age 
(The diabetic children's foundation 2019). 
 
 
 
1.2 Mouse models of Type 1 diabetes 
 
Mouse models of autoimmune diabetes have played a pivotal role in better 
understanding the pathogenesis and designing approaches to therapy. Although several rat 
models exist to study the disease, such as the Zucker Diabetic Fatty (ZDF) and BB rats, this 
section will mainly focus on mouse models in common use (Al-awar et al. 2016). 
 
Mouse models used to study autoimmune diabetes can be broadly divided into two 
categories – humanized and spontaneous models. Humanized models are typically created 
by the introduction of genes such as those encoding for MHC, T-cell receptors and co-
stimulatory molecules taken from humans. These models can aim to achieve the events 
initiating disease by transferring lymphocytes for example (von Herrath and Nepom 2009). 
A recent example of a humanized mouse model is the “YES” mice created by crossing mouse 
strains devoid of mouse MHC class I and II genes, and insulin genes (a known β-cell 
autoantigen). Instead, these mice express both human antigen presenting molecules and 
insulin genes as transgenes to illustrate autoantigen originating epitopes involved in disease 
initiation and heterogeneity in humans (Luce et al. 2018). Thereby, humanized models offer 
the advantage of a more detailed picture of in vivo immunoregulation of particular antigens 
presented in the framework of humanized antigen presenting modules, among other genes 
(von Herrath and Nepom 2009). 
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Spontaneous mouse models of autoimmune diabetes can ensue from pathway 
dysfunctions, insertion of transgenes or precisely known genetic mutations (von Herrath and 
Nepom 2009). For instance, double transgenic mouse models are made to carry transgenic 
expression of a specific antigen under the control of the insulin promoter (Rat Insulin 
promoter: RIP) on their pancreatic β-cells, along with TCR transgenes specific for that 
antigen. An example is the DO11.10 TCR-Tg×RIP-mOVA model, in which ovalbumin is 
expressed as the autoantigen within the pancreas, which along with the DO11.10 TCR 
transgene allows for the expansion of highly diabetogenic OVA-specific CD4+ T-cells. 
These mice become diabetic by 10 weeks of age and offer the advantage of focusing on a 
specific T-cell subset (van Belle, Taylor, and von Herrath 2009). Another popularly used 
model to study autoimmune diabetes is the NOD mice, due to its many similarities to the 
human form of disease. Diabetes initiation in NOD mice is rapid and disease progression is 
responsive to immune modulation (von Herrath and Nepom 2009). The similarities to the 
human form of disease are so striking that this model has been used for over 35 years by 
researchers. In addition, the model allows intrusive procedures and procurement of tissues 
that are seldom obtained from human patients making it a cornerstone for autoimmune 
diabetes research (Chen, Mathews, and Driver 2018). 
 
 
 
 
1.2.1  NOD mouse model 
 
The NOD mice serve as a preclinical model to autoimmune diabetes that outlines the 
immune pathogenesis closest to disease in humans. In addition to striking similarities in 
disease progression, the model provides a deeper understanding on genetic and 
environmental risk factors and therapies targeting various immune pathways. Yet, 
researchers noticed major differences in histopathology in patients and NOD mice, and 
challenges persist in translating therapies from NOD mice to humans (Zeng 2017). 
 
NOD mice spontaneously develop T1D, unlike the majority of animal models that do 
not spontaneously develop autoimmunity. Both NOD mice and humans become diabetic 
early on, with NOD mice at around 10 weeks and humans around 6 months of age up to 
adolescence (Pearson, Wong, and Wen 2016). Genetic susceptibility genes, mainly MHC-
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related genes are similar amongst both species. Autoantigens including GAD, insulin, ZnT8, 
IA-2 and IGRP are alike amongst NOD mice and humans. Both species do not exhibit 
lymphopenia, unlike the BB rat, highlighting one of the many reasons NOD mice have 
become more popularly used to study pathogenesis of T1D. Immune cell infiltration of 
pancreas leading to insulitis is characterized by DCs, macrophages, NK cells, B-cells, CD4 
and CD8-T cells in both species (Pearson, Wong, and Wen 2016). Additionally, neither 
species show a TCR repertoire bias that can be implicated in pathogenesis. However, 
ketoacidosis, a serious side effect of diabetes, is more severe in humans compared to NOD 
mice. Moreover, there is a sex bias, where in NOD mice, a majority of females become 
diabetic, whereas in humans prior to puberty, there is no bias but after puberty, there is a 
slight skew towards males developing the disease. To address some of these differences, 
researchers are developing humanized NOD mouse models to better translate therapies to 
humans. Nevertheless, NOD mice in general and humanized NOD mice have and will 
continue to provide important discoveries into disease pathogenesis in humans (Pearson, 
Wong, and Wen 2016). 
 
 
 
 
1.3 Contribution of genetic and environmental factors in T1D 
 
Both genetics and environmental risk factors are known to play a role in autoimmune 
diabetes development. Recent investigations propose an increasing role for environmental factors 
(Kozhakhmetova and Gillespie 2015). Moreover, the considerable rise in T1D incidence over 
the past 30 years can only be explained by environmental or lifestyle changes (Rewers and 
Ludvigsson 2016a). 
 
 
 
1.3.1 Genetic Factors 
 
 
The MHC gene makes up the highest susceptibility factor contributing to T1D 
development, in both NOD mice and humans. MHC-II molecule I–Ag7, ortholog of HLA-
DQ in humans expressed by NOD mice plays the most significant role in diabetes 
development, compared to other MHC-related molecules (Pearson et al. 2016). A 
polymorphism in MHC-II gene, where serine at position 57 of I–Ag7 in NOD mice is 
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substituted by a charged aspartate residue, is also observed in human HLA-DQ, where 
alanine is substituted in the place of aspartate instead. When serine is replaced at position 57 
with aspartate (as found in wild-type diabetes resistant mice), NOD mice are protected from 
T1D. Similarly, the DR3/4-DQ2/8 haplotypes are highly associated with susceptibility to 
diabetes in humans and protection ensues with other DR and DQ alleles (Pearson et al. 2016). 
 
 
Another important genetic susceptibility factor in humans includes the expression 
level of proinsulin in the thymus. Protection or susceptibility to disease is associated with 
the number of variable numbers of tandem repeats (VNTRs), upstream of the proinsulin gene 
(Pearson et al. 2016). For instance, 140-200+ repeats is correlated with increased thymic 
proinsulin and disease protection, whereas 26-63 repeats is correlated with decreased 
expression of proinsulin within the thymus and increased disease susceptibility (Pearson et 
al. 2016). When NOD mice were designed with insulin levels to mirror human proinsulin 
expression within the thymus, it was observed that increased thymic proinsulin expression 
led to greater negative selection and deletion of insulin autoreactive T-cells during their 
development associated with T1D protection (Pearson et al. 2016).  
 
 
Additionally, variants in genes such as CTLA-4 and PTPN22 also contributes to 
increased disease risk (Pociot et al. 2010). CTLA-4, a checkpoint inhibitory molecule, that 
inhibits T-cell activation was characterized by association mapping using both NOD mice 
and human samples. Disease-linked CTLA-4 haplotypes likely inclines the individual 
towards a failure in peripheral tolerance in various organs or tissues leading to several known 
human autoimmune diseases (Pociot et al. 2010). Similarly, gene variants resulting in amino 
acid substitution of the gene encoding for lymphoid-specific protein tyrosine phosphatase 
(PTPN22) an inhibitor of T-cell activation, have been shown to affect its functionality in 
vitro and in vivo, leading to increased susceptibility to T1D as well as to other autoimmune 
diseases (Pociot et al. 2010). 
 
 
 
 
1.3.2 Environmental Factors 
 
Early epidemiological case studies have linked viruses as a probable trigger for T1D. 
Enteroviruses, among other viruses, have been linked as the strongest cause for pathogenesis 
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in both animal models and humans. Enteroviruses have been found in the pancreas of 
recently diagnosed T1D patients and possess tropism to islets both in vivo and in vitro 
(Rewers and Ludvigsson 2016b). 
 
Dietary factors play a key role in pathogenesis of T1D induction. For instance, 
children breastfed around the time they were introduced to cereals had a decreased risk of 
developing disease, supporting a protective role of breastfeeding (Rewers and Ludvigsson 
2016b). Studies investigating children drinking cows’ milk and its contribution to 
pathogenesis have yielded conflicting results, showing both increased and decreased risk for 
disease development and progression. In children at earlier stages of diabetes, increased 
cows’ milk consumption may promote disease progression. This is thought to be caused by 
specific fatty acids in cows’ milk and meat such as myristic, omega-7, 9, 16:1 and others 
(Virtanen et al. 2010). Vitamin D is a compound studied extensively as a major player in 
immune regulation and metabolic pathways involved in diabetes. However, birth cohort 
investigations have found very little evidence of vitamin D supplementation in protection 
against disease initiation or progression (Rewers and Ludvigsson 2016b).  
 
Studying specific environmental triggers in autoimmune diseases presents a 
challenge as there are infinite candidate factors. Hence, the NOD mice model serves as a 
useful tool to study exactly how these environmental factors act in disease development. 
Some of the factors implicated in diabetes development in NOD mice include alterations in 
gut microbiota, exposure to wheat, gluten as well as to infectious agents (Pearson et al. 2016). 
Presently, a significant international study called TEDDY (The Environmental Determinants 
of Diabetes in the Young) is on-going, tracking young children over time to better understand 
the role of particular environmental risks in disease development (Anon 2007). 
 
 
 
1.4 The immune system in Type 1 Diabetes 
 
Destruction of pancreatic β-cells is a result of immune dysfunction, where both parts 
of the innate and adaptive immune system have been implicated. The past ten years have 
highlighted the role of T-cells in mediating β-cell damage. In healthy individuals, these T-
cells are strictly controlled by various regulatory mechanisms, generally referred to as 
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“immunological tolerance.” Therefore, a break in immune tolerance plays a major role in 
disease development and progression (Hull, Peakman, and Tree 2017). 
 
 
1.4.1  General Pathophysiology 
 
Death of pancreatic β-cells due to a trigger such as viruses for instance, releases 
antigens and initiates the immune reaction towards other β-cells, resulting in ongoing 
inflammation of islets and eventually clinical manifestations of disease. Typically, APCs 
such as DCs and macrophages uptake these β-cell antigens and present them to CD4+ and 
CD8+ T-cells (Saberzadeh-Ardestani et al. 2018). In the periphery, autoreactive T-cells that 
have escaped negative selection in the thymus are activated and mediate β-cell killing by 
signals that include proinflammatory cytokine secretion and extrinsic apoptotic pathways 
involving Fas-FasL interactions of T-cells, increasing β-cell sensitivity to apoptosis (Paschou 
et al. 2018). In addition, cytokines secreted by APCs such as macrophages also harm β-cells, 
further sensitizing them to killing. Before T1D onset, persistent atrophic inflammation of the 
islets is detected, where T-cells, DCs, macrophages and B-cells are implicated. At this stage, 
patients are often asymptomatic and once this condition continues over several months or 
years, clinical manifestations of symptoms are observed. Several autoantibodies towards β-
cell antigens can also be present prior to clinical symptoms in patients (Paschou et al. 2018). 
Overall, β-cell killing by effector mechanisms involves the combined co-operation of various 
APCs such as DCs, macrophages, B cells, as well as other members of the innate immune 
system such as NK cells and importantly, adaptive immune cells CD4+ and CD8+ T-cells 
(Saberzadeh-Ardestani et al. 2018). As gatekeepers of the immune system, Tregs function 
by various mechanisms to primarily suppress the inflammatory processes mediated by other 
immune cells (Hull et al. 2017). The specific roles of key immune cells involved in disease 
initiation and progression will be discussed in detail in the following sections. 
 
1.4.2  Role of Antigen Presenting Cells (APCs) 
 
It is well established that presentation of self-antigens by APCs to developing 
thymocytes or peripheral T-cells is necessary for all mechanisms leading to tolerance, either 
through deletion, anergy or Treg induction. T-cell responses are partly controlled by APCs 
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that upon interaction can inhibit inflammatory immune responses. Professional APCs such 
as DCs, macrophages and B cells are most widely investigated, and these APCs are a two-
edged sword in the context of T1D as they can be primed towards either pro-inflammatory 
or anti-inflammatory immunogenic operations (Creusot, Postigo-Fernandez, and 
Teteloshvili 2018). 
 
1.4.2.1 Role of Dendritic Cells (DCs) 
 
DCs are professional antigen presenting cells that are characterized by phenotype 
heterogeneity endowed with different immune functions. Main functional DC 
subpopulations are conserved between mice and humans. Abnormal DC activation is enough 
to cause autoimmunity and cell-intrinsic mechanisms exist to negatively regulate DC 
activation to prevent autoimmunity. DCs can prime naïve CD4+ and CD8+ T-cells, which 
depending on the immune milieu, can promote or restrict autoimmunity. It has been shown 
that DCs can prime naïve CD4+ T-cells to become T-follicular helper (Tfh) cells that are 
implicated in systemic lupus erythematosus (SLE) (Ganguly et al. 2013). Similarly, DCs can 
prime naïve CD4+ T-cells to become Th17 cells implicated in psoriasis and experimental 
autoimmune encephalomyelitis (EAE) (Ganguly et al. 2013). In T1D, DCs can prime naïve 
CD4+ T-cells to become Th1 cells that are heavily implicated in disease development, or 
conversely, to Tregs that can result in disease restriction (Ganguly et al. 2013). DCs can also 
interact with autoreactive CD8+ T-cells to induce their proliferation and to increase their 
effector activity that contributes to disease initiation and progression. (Ganguly et al. 2013). 
 
DCs play central roles during all stages of T1D pathogenesis as key activators of 
naïve T-cells and in upkeeping self-tolerance. DCs within the pancreas uptake β-cell 
autoantigens and migrate to the pancreatic draining lymph nodes (LNs). In the LN they can 
prime naïve CD4+ and CD8+ T-cells, which, conditional on signals received by DCs, can 
differentiate into Th1 inflammatory effector subsets or Th2 anti-inflammatory or Tregs 
(Morel 2013). Activated T-cells then infiltrate the islets and perform their respective 
functions. There are two main subsets of DCs – plasmacytoid and classical. Both subsets 
have disease inducing and protective roles. Classical DCs (cDCs) contain certain 
subpopulations, such as merocytic DC, that can present autoantigens and home in inflamed 
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islets, propagating disease (Morel 2013). These DCs can release large amounts of IL-12 that 
promote Th1 responses and induce more pro-inflammatory cytokine secretion by T-cells and 
NK cells. TNF-α and IL-1β production by these subpopulations of cDCs can also induce DC 
maturation and result in a breakdown of immune tolerance (Morel 2013). Finally, they can 
also cross-present antigen to CD8+ T-cells resulting in increased effector T-cell activity. 
Protective subsets of cDCs such as the CD11b subset can be responsible for Treg induction, 
as well as interacting with thymic Tregs to influence their migration, and PD-1/PD-L1 
interaction with T-cells resulting in T-cell anergy. Plasmacytoid DCs (pDCs) are high 
producers of type 1 interferons (IFN). In NOD mice, it has been shown that crosstalk between 
B-1a B cells, neutrophils and pDCs is involved in T1D induction through IFN production 
(Diana et al. 2013). However, it has been proposed that viral infection leading to T1D is 
dependent on virus tropism and the local milieu where IFN in produced. Thus, on one hand 
a pancreatic virus can stimulate IFN production protecting islets whereas, on another hand, 
IFN production by pDCs can activate autoreactive T-cells and result in T1D progression. 
Additionally, in agreement with pathogenic role pDCs in T1D, it was observed that pDC 
depletion decreased diabetes incidence in NOD mice (Morel 2013a). 
 
DCs capacity to be manipulated, to re-establish T-cell tolerance and moderate 
autoantibody production has made them attractive therapeutic targets. A better understanding 
of DC key functions in autoimmunity can help enhance their tolerogenic functions. DCs of 
a semi-mature phenotype exhibiting decreased pro-inflammatory cytokine secretion but 
increased co-stimulatory and MHC molecules expression are considered efficiently 
tolerogenic in protection against autoimmunity. Additionally, tolerogenic DCs function to 
induce Treg cells or other regulatory mechanisms such as Th2 cells, including their 
expansion (Morel 2013a). Tolerogenic DCs have already began to be used in clinics, 
however effective translation of various other DC-based immunotherapies yet needs 
substantial research (Coutant and Miossec 2016). 
 
1.4.2.2 Role of Monocytes/Macrophages 
 
Macrophages are known to play important roles in T1D pathogenesis. They take up 
and present autoantigens to T-cells, regulate T-cell responses and CD4+ T-cell 
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differentiation into various T helper subsets by secreting cytokines, thereby influencing 
immune homeostasis (Espinoza-Jiménez, Peón, and Terrazas 2012). 
 
Emerging studies suggest that macrophages are also implicated in the later stages of 
T1D. For instance, transferred diabetogenic T-cells (lymphocytes directly or indirectly 
responsible for β-cell death due to their antigen specificity, migratory capacity and ultimately 
cytotoxic function)  were unable to cause diabetes post monocyte depletion, and it was shown 
that in vitro activated macrophages can directly destroy β-cells (Martin et al. 2008), (Roep 
and Peakman, 2011). Nevertheless, evidence for the latter is minimal and is still under 
investigation One study using several transgenic mouse models showed that monocytes can 
home to the islets when CCL2 chemokine is expressed in β-cells, killing β-cells and leading 
to diabetes, without mature T- and B- cell involvement (Martin et al. 2008). Despite the fact 
that diabetogenic T- and B-cells are key players in the pathogenesis of T1D in physiological 
environment, the study by Martin et al. (2008) and others have implicated 
monocytes/macrophages to play also a crucial role in pathogenesis. CCL2 is a key 
chemokine molecule responsible for recruiting monocytes and other immune cells to sites of 
inflammation. One important implication of the mentioned study is targeting CCL2 in APCs 
to decrease recruitment of autoreactive cells that home to sites of ongoing inflammation. In 
fact, it has been observed that anti-CCL2 therapy can oppose other autoimmune diseases 
such as lupus nephritis and murine demyelinating disease in animal models and several 
CCL2 inhibitors are currently under development (Yang 2008). Challenges are present in 
translating this therapy to humans, and investigations with respect to redundancy in 
chemokine pathways, in terms of the impact of modifying one chemokine pathway is yet to 
be determined (Yang 2008). 
 
1.4.2.3 Role of B-cells 
 
B-cells constitute the immune cell infiltrates in pancreatic islets in both mice and 
humans. In NOD mice, B-cells were found during the 4-7 weeks, age at which about 10% of 
islets are infiltrated. The role of B-cells in pathogenesis of T1D has been theorized to be most 
likely multifaceted, composing of faulty B-cell tolerance that permits autoreactive cells to 
escape and persist in the periphery, and remain activated well before the effector phases of 
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T1D (Hinman and Cambier 2014). B-cells, as APCs play a primary role in presenting β-cell 
autoantigens to diabetogenic T-cells. It was reported that in NOD mice, inhibition of antigen 
presentation by MHC-I or MHC-II on B-cells averts T1D development, highlighting the 
importance of B-cells as antigen presenters to CD4+ T-cells and cross-presentation to CD8+ 
T-cells (Noorchashm et al. 1999). They also exert effector mechanisms via the secretion of 
cytokines and autoantibodies towards islet autoantigens. 
 
Although T1D is considered to be mainly a T-cell mediated disease, there has been 
considerable evidence highlighting a crucial role of B-cells in pathogenesis. In NOD mice, 
depletion of B-cells prevents diabetes development and additionally, depletion of B-cells in 
recently diagnosed T1D patients using the monoclonal antibody rituximab (chimeric 
mouse/human monoclonal IgG1 kappa antibody targeted against the CD20 antigen), 
conserved β-cell function and postponed the need for insulin administration 1 year post 
treatment (Smith, Simmons, and Cambier 2017). Overall these results suggest a considerable 
role of B-cells in disease development (Smith, Simmons, and Cambier 2017). As therapy, 
depleting B-cells will mostly not be distributed in clinical use and alternative minimal risk 
B-cell targeted therapy is still undergoing investigation (Hinman and Cambier 2014). 
 
1.4.3 Role of T-lymphocytes 
 
Autoantibodies characterize biomarkers used for T1D diagnoses and autoreactive T-
lymphocytes are considered critical mediators of β-cell killing. Approximately 50-60% of 
genetic predisposition to T1D comes from HLA alleles that encode genes responsible for 
antigen presentation of peptides to T-cells (Pugliese 2017). Examination of T1D organ donor 
pancreas initially showed evidence of shared TCR sequences against target antigens that are 
shared amongst patients, as well as a wide repertoire of self antigens implicating the TCR in 
the insulitis lesions within the pancreas. Although both CD4+ and CD8+ T-cells are 
implicated in pathogenesis, CD8+ T-cells constitute the majority of T-cells that mediate 
inflammation seen in insulitis (Pugliese 2017). 
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1.4.3.1 T-cell origin and development 
 
In mammals, T-cell development starts with haematopoietic stem cells (HSC) within 
the fetal liver and afterwards in the bone marrow where they differentiate into multipotent 
progenitors. Upon initiating transcription of recombination activating gene 1 and 2 (RAG 1 
and 2), a subclass of multipotent progenitors develops into lymphoid-primed multipotent 
progenitors and then to common lymphoid progenitors (Cano and Lopera. 2013). Amongst 
all pluripotent cells, only a small portion will migrate to the thymus and differentiate into 
early thymic progenitor (ETP) cells. These ETP cells are multipotent, and can become T-
cells, B-cells, NK cells, myeloid cells and DCs. Long-term thymopoiesis is solely dependent 
on the recruitment of thymus-inhabiting progenitors since the thymus itself does not 
encompass self-renewing progenitors. T-cell development to maturity is therefore 
conditional on progenitors entering the thymus within specific niches that allow compulsory 
stage-specific events needed for differentiation of progenitors to be reprogrammed into 
functional T-cells (Cano and Lopera. 2013). 
 
ETP cells that are attracted by CCL9 and CCL21 chemokines come into the thymus 
by the corticomedullary junction (Cano and Lopera. 2013). Within the thymus stroma, the 
ETP come across several ligands for the notch receptors and growth factors such as Kit-
ligand and IL-7, that aid in differentiation of these cells in the early stages of T-cell 
development. In fact, expression of notch-1 receptors and their contact with delta-like 
ligands is necessary for the expansion of T-cells within the thymus and for inhibiting non-T 
cell lineage maturation. ETP differentiate into double negative (DN) cells in the thymic 
cortex, i.e. they are both CD4- and CD8-. During this stage, ETP lose the ability to become 
B-cells and initiate expression of proteins necessary for the TCR gene arrangement like 
RAG1 and 2 (Cano and Lopera. 2013). Subsequently, proteins critical for TCR construction 
and signaling are also expressed, such as the CD3 chains, kinases, and phosphatases like 
LCK, ZAP70 and LAT. During the DN3 stage, there is cell-cycle arrest which allows for the 
rearrangement of the TCR β genes encoding for the variable region of the antigen receptors. 
TCR β genes that have been productively rearranged through V(D)J recombination, are then 
coupled to a surrogate chain pre-Tα, which forms the pre-TCR.  Signaling through the pre-
TCR allows cells to survive, proliferate and differentiate, in a process termed β selection. 
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Following the β selection checkpoint, thymocytes go on to become double positive 
(CD4+CD8+) cells, that undergo TCRα rearrangement, leading to an entirely assembled 
TCR (Cano and Lopera. 2013). Following the DP stage, cells undergo positive selection, 
where cells with functional TCRs are put to the test by their ability to bind self-peptides 
presented by epithelial cells via MHC-1 or MHC-II with intermediate affinity. Positive 
selection permits differentiation of DP thymocytes to single positive (SP) cells, restricted to 
their respective MHC classes. DP thymocytes unable to bind MHC-I or MHC-II go through 
apoptosis and only a subset of the DP cells expressing TCR with intermediate affinity 
towards the self-antigens live via survival signals. Afterwards, SP cells undergo negative 
selection upon entering the thymic medulla where medullary thymic epithelial cells (mTEC) 
and DCs present a variety of self-antigens to developing thymocytes. Genes expressed by 
mTECs include many tissue-restricted self-antigens. SP cells reacting with high affinity for 
binding self-antigens presented in the context of MHC-I or MHC-II die by apoptosis, thereby 
securing the death of possible autoreactive cells. Upon surviving negative selection, cells 
mature and complete their development into naïve T-cells. Naïve T-cells can then exit the 
thymus and migrate to the secondary lymphoid organs where they can encounter antigens, 
be primed and differentiate into effector T-cells with unique functionalities (Cano and 
Lopera. 2013). 
 
1.4.3.2 Implication of CD4+ T-cells in T1D 
 
Although CD8+ T-cells are primarily implicated in islet infiltration and 
inflammation, CD4+ T-cells are involved in ‘licencing’ CD8+ T-cells to be optimally 
activated to perform effector function (Katz, Benoist, and Mathis 1995). Additionally, CD4+ 
T-cells can differentiate into various T helper subsets after activation, and this choice has 
critical effects on their ensuing cytokine production and migration. Differentiation into a 
specific subtype also determines the nature of interaction between T-cells and other immune 
cells, thereby directly influencing effector functions. T-cell differentiation was mainly 
focused on T helper 1 (Th1) and T helper 2 (Th2) responses in terms of T1D, which was 
primarily seen as a Th1-mediated disease. However, over the years this view has expanded 
to include various other subsets such as Th17 and follicular T-helper cells (Tfh) (Katz, 
Benoist, and Mathis 1995). 
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Early evidence that T1D is a Th1 mediated disease came from a study showing that 
T-cells expressing a diabetogenic TCR differentiating towards Th1 and not Th2 phenotype, 
caused diabetes in neonatal NOD mice (Katz et al. 1995). Considering the Th1 phenotype 
includes IFN-γ dominated responses, rising levels of IFN-γ was observed to be correlated 
with T1D progression in NOD mice, and appeared to be a necessity in a virus-induced 
diabetes model (von Herrath and Oldstone 1997). Numerous studies have highlighted a role 
for IFN-γ in disease progression (Walker and von Herrath 2016). For instance, IFN-γ 
expression under control of human insulin promotor was enough to initiate diabetes 
development in mice, and IFN-γ inhibition in NOD mice could avert disease (Sarvetnick et 
al. 1988). Mechanisms of action of IFN-γ include up-regulation of MHC class I and II, 
increasing macrophage activation, stimulating adhesion molecule and chemokine expression 
to drive leucocyte extravasation, increasing the homing of autoreactive T-cells to pancreatic 
islets in NOD mice, and directly killing β-cells (Walker and von Herrath 2016). It is known 
that Th2 responses inhibit Th1, resulting in the ability of one T-cell subset reciprocally 
preventing the functionality of the other. As IL-4 is predominantly a Th2-type response, 
exogenous administration of IL-4 prevented diabetes in NOD mice, and transgenic 
expression of IL-4 under control of the insulin promoter in the pancreatic islets inhibited 
diabetes initiation (Rapoport 1993). Interestingly, helminth disease, known to promote Th2 
response was shown to be protective against diabetes in NOD mice (Zaccone and Cooke 
2013). 
 
One important area of study of Th17 cells in T1D is the role of these cells to 
simultaneously produce IL-17 and IFN-γ. CD4+ T-cells secreting IL-17 has been implicated 
in many rodent disease models highlighting an importance for these cells in disease pathways 
in humans (Arif et al. 2011). For example, in multiple sclerosis, IL-17 gene expression is 
upregulated in plaques of the brain and IL-17 is expressed at increased levels by circulating 
T-cells. Similarly, Th17 cells that infiltrate synovial tissue is highly implicated in rheumatoid 
arthritis, where IL-17 promotes osteoclast-facilitated bone resorption (Arif et al. 2011). In 
human T1D, IL-17 has been directly linked to β-cell death. Pro-inflammatory cytokines such 
as IL-1β and IFN-γ cause upregulation of the IL-17 receptor which leaves β-cells greatly 
susceptible to apoptosis by IFN-γ, IL-17, IL-1β cytokines (Arif et al. 2011). T-cells positive 
for IL-17 can instigate IFN‐γ secretion leading to T-cells co-expressing both cytokines. 
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Several evidences exist to support a role of these cells in pathogenesis of T1D, including 
children exhibiting co-production of both cytokines, and mRNA levels of both cytokines 
being up-regulated within the pancreatic islets of a patient who died 5 days within disease 
diagnosis (Arif et al. 2011). Studies have demonstrated an increased tendency of IL-17+ T-
cells to produce IFN‐γ in children diagnosed with T1D compared to healthy individuals 
(Walker and von Herrath 2016). Cumulatively, these studies warrant further investigation of 
T-cells co-producing IL-17 and IFN‐γ in relation to disease progression. 
 
Tfh cells have also been implicated in diabetes in both humans and mouse models of 
T1D. Tfh cells secrete mainly IL-21, and this subset specifically helps B-cells in antibody 
production. As their name suggests, Tfh cells go into B-cell follicles of secondary lymphoid 
tissue where they begin the formation of specialized structures known as germinal centers 
(Walker and von Herrath 2016). Within these germinal centers, B-cells re-arrange their 
immunoglobulin molecules so that ones with the highest affinity for the antigen can be 
designated to become memory B-cells and long-lived plasma cells (Walker and von Herrath 
2016). Microarray analysis of T-cells towards islet antigens in the pancreatic lymph nodes 
revealed an increase in Tfh cell specific genes including CXCR5 and IL-21 (Walker and von 
Herrath 2016). Adoptive transfer of CXCR5 enriched T-cells were shown to preferentially 
induce diabetes in mice (Walker and von Herrath 2016). In humans, increased Tfh 
phenotype, IL-21 production after ex-vivo activation of memory T-cells and in the blood 
circulation was reported in T1D patients compared to non-diabetic healthy controls (Walker 
and von Herrath 2016). The consequences of IL-21 production by CD4+ T-cells include 
facilitating their survival, increasing the ability of macrophages ability to stimulate CD4+ T-
cell proliferation and by opposing Treg suppressive function. Additionally, IL-21 has also 
been critically implicated in T- B cell interactions which may be pertinent in the role of B-
cells in disease (Walker and von Herrath 2016). Since IL-21 can be produced by other T-cell 
populations including Th17 cells and induced regulatory Tr1 type cells, the involvement of 
non-Tfh subsets in disease progression cannot be omitted. However, one study showed a 
strong significant correlation between Tfh frequency and IL-21+ T-cells, suggesting a crucial 
role of Tfh cells as major sources of IL-21 in T1D (Ferreira et al. 2015). 
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To elucidate the mechanisms by which CD4+ and CD8+ T-cells collaborate in islet 
β-cell killing, one study used two-photon microscopy in-vivo to follow hemagglutinin (HA) 
specific CD4+ and CD8+ T-cells within mice pancreatic β-cells expressing the HA antigen 
(Espinosa-Carrasco et al. 2018). They found that infiltrating CD4+ T-cells alone were 
enough to recruit APCs in the exocrine tissue that express increased MHC class II (mostly 
consisting of CD103+ DCs), leading to increased T-cell arrest in tissue. Effector CD8+ T-
cells that lacked persistent help by APCs via anti-MHC II antibody treatment were unable to 
sustain optimal effector functions and exhibited decreased infiltration, uniquely in the 
pancreas thereby impeding disease progression. These results highlight a critical role of 
effector CD4+ T helper cells in continually helping effector CTL functions at target 
environments via APCs (Espinosa-Carrasco et al. 2018). 
 
Protective subtypes of CD4+ T-cells such as Tregs and Tr1 cells with suppressive 
function have been shown to downregulate immune responses and protect against diabetes. 
Tregs are considered the gatekeepers of autoimmunity by keeping unwarranted responses at 
bay to inhibit disease development. Thorough characterization of Tregs including their 
generation in vitro and in vivo serves as a whole new venue to treating autoimmune diseases 
(Varela-Calvino et al. 2017). The mechanisms of action of these cells will be discussed in 
further detail in later sections. 
 
1.4.3.3 Implication of CD8+ T-cells in T1D 
 
CD8+ T-cells or cytotoxic T-lymphocytes (CTLs) specific towards insulin or other 
autoantigens are crucial for T1D development in both humans and mice. CTLs that recognize 
autoantigens presented via MHC-I kill β-cells using various mechanisms including via the 
release of perforin and granzyme (Burrack, Martinov, and Fife 2017). In diabetic patients, 
most of the infiltrating cells of the pancreas are CTLs, along with overexpression of MHC-I 
on β-cells. CTLs are also known to produce elevated amounts of IFN-γ that upregulate Fas 
expression on beta cells and therefore enabling CTLs to use Fas/FasL mechanisms to destroy 
β-cells. Naïve CD8+ T-cells recognize antigens presented by APCs and become activated. 
The proliferation, survival and development of naïve CD8+ T-cells as they differentiate into 
CTLs is promoted by various factors including IL-12, IFN-α, IFN-β, IFN-γ, and mTOR 
(Deng et al. 2019). Eomes and T-bet transcription factors enhance the expansion of memory 
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CD8+ T-cells and their effector function (Pearce et al. 2003). Studies suggest T-bet and 
Eomes function collaboratively to activate genes encoding for IFN-γ, perforin and granzyme 
in CTLs (Pearce et al. 2003). Eomes+/−Tbx21−/− (Tbx21 is a Th1-cell specific transcription 
factor that mediates the expression of the key Th1 cytokine, IFN-γ) mice have dysfunctional 
IFN-γ induction and effector CD8+ T-cell activity (Pearce et al. 2003). Upon CTL killing of 
target cells, there is a release of several autoantigens which leads to increased production of 
autoantibodies that can result in self-apoptosis and increased local inflammation. Thus, 
CD8+ T-cell interaction with β-cells causes β-cell killing and an increase in autoreactive T-
cells within islets (Deng et al. 2019). 
 
Studies have demonstrated a role of micro-RNAs (miRNAs) in CD8+ T-cells with 
regards to gene silencing in T1D. Using adoptive transfer models of T1D, it has been shown 
that downregulating miR-29b reduced CD8+ T-cell cytolytic functions (Deng et al. 2019). 
Certain miRNAs such as miR-23b, miR-98 and miR-590-5p can decrease the expression of 
crucial apoptotic molecules, like Fas and TNF-related apoptosis-inducing ligand (TRAIL), 
suggesting they can act to modify T1D susceptibility in patients. Studies in epigenetic 
regulation of CD8+ T-cells in autoimmunity, and developing relevant therapeutic 
interventions are ongoing (Deng et al. 2019). 
 
Recent investigations have reported a subset of CD8+ T-cells playing a suppressive 
role in autoimmunity, tumors and infections (Deng et al. 2019). These cells are characterized 
by the expression of the Treg specific master regulatory gene forkhead box p3 (Foxp3), the 
high affinity IL-2 receptor CD25, and inhibitory molecules such as PD-1, CTLA-4 and LAG- 
 
3. These CD8+ Tregs can suppress effector T-cell responses in vitro in a CTLA-4 dependent 
manner. However, compared to CD4+ Tregs, CD8+ Tregs are less commonly studied and 
further investigation is required for their mechanisms of action (Deng et al. 2019). 
 
 
 
1.4.4 Role of Regulatory T-cells 
 
Regulatory T-cells (Tregs) are key immune suppressor cells that maintain peripheral 
tolerance. Decreased Tregs and/or their impaired suppression can lead to autoimmunity. 
Growing evidence in mouse models of various autoimmune disorders, including T1D, have 
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shown impairment in Treg suppressive function. Although in human diabetic patients, the 
frequency of Tregs in peripheral blood is normal, studies have shown these Tregs to have 
decreased suppressive function compared to Tregs of healthy controls (Visperas and Vignali 
2016a). 
 
There are two main classes of Tregs– natural or thymic-derived Tregs (nTregs) and 
inducible Tregs (iTregs) that can be differentiated in vitro via cytokines such as IL-10, IL-
35 and TGF-β (Vignali 2012). This section will discuss various mechanisms by which Tregs 
suppress immune responses, highlighting the role of checkpoint inhibitory molecules, and 
how overall Treg suppression is impaired in T1D. 
 
 
1.4.4.1 Specificity of Regulatory T-cells 
 
Tregs are hallmark cells required to maintain self-tolerance, as well as towards 
unharmful, regular environmental antigens encountered at mucosal surfaces day by day 
(Bacher et al. 2016). Human target Treg antigens that promote mucosal tolerance are 
currently undergoing investigation. In mice, Treg specificity is largely influenced by self-
antigens, and Tregs require continuous stimulation through the TCR by self-antigens to 
inhibit autoimmunity. Yet, exogenous antigen specific Tregs have been identified in naïve 
and pathogen-infected mice, as well as humans (Bacher et al. 2016). Murine Tregs specific 
for microbiota antigens were detected in intestinal tissues, and additionally, murine Tregs 
maintain tolerance towards fetal antigens during pregnancy. This provides evidence that 
Tregs are not solely a self-responsive population and they exist to also promote tolerance 
towards innocuous exogenous antigens. However, studies of the function of Treg tolerance 
towards aeroantigens is lacking and requires investigation (Bacher et al. 2016). One study 
by Spence et. al (2018) showed an accumulation of Tregs in inflamed islets, experienced 
in self-antigens, using NOD mice. Although progress has been made in mapping the 
specificity of autoreactive T-cells in T1D, Treg specificities that influence disease 
progression have not been established. Difficulties in mapping Treg specificities is partially 
due to the naturally extensive Treg repertoire and the comparative infrequency of islet 
antigen-specific Tregs. The challenge in measuring Treg suppressive function in diabetes 
protection in vivo also compounds the complexity of determining Treg specificity. 
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Interestingly, the group of Spence et. al (2018) performed MHC tetramer staining and 
single-cell TCR analysis of Tregs in islets of NOD mice to determine their specificity for 
insulin and various islet-derived antigens. NOD mice were found to be enriched in insulin-
specific antigens in inflamed islets, an unexpected finding regarding the increased 
localization and prominence. It was shown that diabetes-susceptible recipients of Tregs 
from inflamed islets were protected from disease progression, although NOD mice 
eventually succumb to disease most likely due to IL-2 scarcity within inflamed islets and 
exhaustion of Tregs specific for islet-specific antigens. Overall, engineering Treg 
specificities based on insulin specific TCRs can be used as treatment for protection of β-
cells in T1D, highlighting an important field of study regarding the specificities of Tregs 
in the context of autoimmunity (Spence et. al 2018).  
 
 
1.4.4.2 Mechanisms of Suppression 
 
CD4+CD25+Foxp3+ Tregs are key mediators of peripheral tolerance as they can 
suppress various immune cells such as B cells, NK cells, NKT cells, monocytes, DCs, CD4+ 
and CD8+ T-cells. 
 
 
In order for Tregs to optimally suppress immune cells, Tregs have to be activated 
through their TCR in the presence of IL-2, although co-stimulation by CD28 is less stringent 
of a requirement (Schmidt, Oberle, and Krammer 2012). The majority of nTregs 
constitutively expresses the high affinity IL-2 receptor chain CD25 during their development 
in the thymus and their functionality is dependent on the expression of the transcription factor 
Foxp3. Primarily, Tregs were shown to have suppressive function when their depletion 
resulted in CD4+ T-cell mediated autoimmunity (Miyara and Sakaguchi 2007). Treg 
suppressive mechanisms that are best studied include the secretion of inhibitory cytokines, 
expression of checkpoint inhibitory receptors such as CTLA-4, LAG-3, cytotoxicity such as 
the granzyme/perforin pathway and metabolic interference such as depletion of IL-2 from 
the local environment (Vignali 2012). 
 
 
Tregs can secrete large amounts of soluble and membrane-bound TGF-β. Inhibiting 
TGF-β partly blocked suppression of T-cell proliferation of both murine and human T-cells 
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in vitro (Schmidt et al. 2012). Additionally, TGF-β1 deficient mice develop T-cell mediated 
autoimmune disease after a few weeks post-birth. Although this is controversial as other 
groups did not find any relation to TGF-β in Treg suppression of T-cells (Schmidt et al. 
2012). Studies have shown that even though TGF-β deficient Tregs can inhibit proliferation 
of T-cells in vitro, in a colitis model, TGF-β1 secretion by Tregs was essential in preventing 
disease (Schmidt et al. 2012). Moreover, TGF-βRII deletion on conventional T cells did not 
render T-cells to be suppressed in vivo in colitis models, however TGF-β secreted by other 
cells than Tregs was probably implicated in these models of colitis instead (Schmidt et al. 
2012). Tregs production of IL-10 was shown to be essential in regulating IFN-γ production 
by T-cells in the inflamed skin (Schmidt et al. 2012), although studies show it to be less 
necessary in controlling IFN-γ and T-cell proliferation in the lymph node (Schmidt et al. 
2012). IL-10 mediated suppression of several immune cells including DCs has been well 
established, however direct action of IL-10 on memory/effector T-cells is essential in 
preventing T-cell mediated colitis. Studies have shown that IL-10R signaling is necessary 
for Tregs and in Th17 cells to optimally suppress colonic Th17 responses (Schmidt et al. 
2012). In vitro experiments have demonstrated that through the action of IL-10, Tregs can 
induce the expression of V-set domain-containing T-cell activation inhibitor 1 (VTCN-1), 
the immune checkpoint molecule on DCs (Miyara and Sakaguchi 2007). IL-35 is a recently 
studied cytokine shown to play a role in Treg suppression by directly preventing 
conventional T-cell proliferation (Collison et al. 2010). IL-4 has been studied to be one of 
the tolerogenic cytokines in several autoimmune animal models and in clinical backgrounds. 
One study used IL-4 knockout (KO) mice to investigate how IL-4 acts on Treg-mediated 
suppression. Even though IL-4 KO and control mice showed similar Treg frequencies, Tregs 
from IL-4 KO mice had reduced suppression of conventional T-cells (Yang et al. 2017). 
 
 
Tregs can also kill effector cells, as a way of inhibiting their action and leading to 
immune suppression (Miyara and Sakaguchi 2007). Perforin and granzyme A secretion can 
result in death of T-cells, monocytes and DCs. Secretion of granzyme B can lead to T-cell 
and B-cell death in a perforin-independent and perforin-dependent manner, respectively 
(Miyara and Sakaguchi 2007). Although inducing cell death is one mechanism of Treg-
mediated suppression, it cannot account for all aspects, as nTregs can cause anergy and 
utilize other suppressive mechanisms to inhibit T-cell and APC effector function. 
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Another mechanisms by which Tregs can induce apoptosis of effector T-cells is by 
IL-2 deprivation. The majority of Tregs constitutively expresses CD25, the high-affinity IL-
2 receptor, and Tregs have been shown to be significantly decreased in IL-2 deficient mice 
(Miyara and Sakaguchi 2007). Administration of anti-IL-2 antibody leading to neutralization 
of circulating IL-2 decreases the frequency of Tregs, causing organ-specific autoimmunity, 
mirroring the effects of Treg depletion (Miyara and Sakaguchi 2007). These studies show a 
crucial role of IL-2 in Treg survival in the periphery and furthermore, IL-2 is necessary for 
Treg activation. IL-2 can upregulate Foxp3 expression by the signal transducer and activation 
of transcription 3 (STAT-3) and STAT-5 -dependent pathways (Miyara and Sakaguchi 
2007). Mechanism of Treg-mediated IL-2 suppression mainly involves leaving less IL-2 for 
conventional T-cells, as Tregs express the high affinity IL-2 receptor (CD25). This lack of 
IL-2 in the environment leaves conventional T-cells with reduced activation, proliferation 
and ultimately their effector functions (de Sousa Linhares et al. 2018). 
 
 
Tregs can also suppress responder T-cells by cell-to-cell contact mechanisms. 
Checkpoint inhibitory molecules such as PD-1, CTLA-4 and LAG-3 are constitutively 
expressed on Tregs, and their expression is upregulated following Treg activation. 
Additionally, these molecules are also expressed by other T-cells. The expression of 
checkpoint inhibitory molecules on Tregs and T-cells play key roles in sustaining peripheral 
tolerance (Paluch et al. 2018). Signaling via checkpoint inhibitory receptors leads to 
inhibition of various immune cells and stops excessive or unwarranted activation. Studies 
have shown that deletion or blockade of these molecules causes autoimmune disease in mice 
(Paluch et al. 2018). On the other hand, stimulation of signaling via these checkpoint 
inhibitory pathways can lead to abrogation of unwarranted immune activation and responses, 
such as in autoimmune diseases (Gianchecchi and Fierabracci 2018a). The mechanisms by 
which these molecules function to inhibit immune cells will be further discussed in the 
following subsection. 
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1.4.4.3 Checkpoint Inhibitory Molecules in Treg Suppression 
 
Key co-stimulatory molecules include CD28, ICOS, TNFR-II, OX40 etc. and these 
molecules play a role in T-cell antigen priming, proliferation, survival and effector functions. 
In contrast, checkpoint inhibitory molecules such as PD-1, CTLA-4 and LAG-3 play a 
crucial role in downregulating the immune response by providing feedback inhibitory signals 
(Kumar, Bhattacharya, and Prabhakar 2018). 
 
PD-1 recognizes two ligands, PD-L1 and PD-L2. PD-L1 is expressed widely on cells, 
such as T and B-cells, DCs, macrophages, mesenchymal stem cells and bone marrow-derived 
mast cells. On the other hand, PD-L2 expression is limited to mostly macrophages and DCs. 
Upon interaction with its ligand, PD-1 acts to inhibit T-cell proliferation, cytokine secretion 
and cytotoxic activity (Gianchecchi and Fierabracci 2018a) . Binding of PD-1 to its ligands 
during an ongoing T-cell effector response causes phosphorylation of tyrosine-based switch 
motif of PD-1, leading to recruitment of tyrosine phosphatase SHP-2. SHP-2 recruitment 
leads to dephosphorylation of Zeta chain Associated Protein Kinase (ZAP70) in T-cells, 
which along with subsequent inhibition of downstream PKC-θ signaling, results in inhibition 
of T-cell activation. Additionally, PD-1 signaling suppresses cell cycle progression that is 
induced via TCR signaling by suppressing casein kinase-2 (CK2), a suppressor of PTEN 
activation. Therefore, increased PTEN function inhibits downstream events of TCR 
signaling leading to decreased T-cell expansion and survival. PD-1 signaling has also been 
shown to decrease TCR expression by causing its internalization by augmenting the 
expression of E3-ubiquitin ligases (Riella et al. 2012). Additional consequences of PD-1 
signaling include reduced expression of transcription factors such as GATA-3, T-bet and 
Eomes, which are linked to effector functions in T-cells, and reduced cytokine production. 
PD-1 signaling is also involved in reversing the dwell time of T-cells and their interaction 
with APCs, which can result in reduced T-cell activation and may induce generation of Tregs 
(Riella et al. 2012). 
 
CLTA-4 recognizes CD80 and CD86 on APCs, the same ligands that are also 
recognized by CD28. CD28 signaling facilitates T-cell activation whereas CTLA-4 opposes 
T-cell activation via inhibitory signals and even binds ligands with stronger affinity than 
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CD28 (Walker 2013). Mechanisms of CTLA-4-mediated inhibition include 1) competition 
between ligands shared with costimulatory molecule CD28, 2) disturbance of localization of 
CD28 in the immunological synapse, 3) suppression of TCR mediated signaling pathways 
via recruitment of PP2A and SHP-2 phosphatases and 4) decreasing interaction time between 
naïve T-cells and APCs. One study investigated the protein structure versus function of 
CTLA-4 in suppression and found that Treg mediated inhibition and anergy were carried out 
by the external domain of CTLA-4 by binding APC costimulatory ligands, whereas the 
internal domain of CTLA-4 mediated TCR hypo-signaling (Tai et. al 2012). The 
externalization of CTLA-4 was required for suppression by either sequestering or 
eliminating costimulatory ligands from the surface of APCs. CTLA-4 externalization has 
also been shown to induce APCs to release indoleamine 2,3 -dioxygenase, which inhibits the 
activation of naïve T-cells metabolically (Tai et. al 2012). 
 
LAG-3 recognizes MHC class II, a CD4 binding homolog, with higher affinity than 
CD4. Majority of the studies examining LAG-3 mediated inhibition has shown LAG-3 to 
associate with CD3, and its crosslinking with CD3 suppresses T-cell expansion, cytokine 
secretion and calcium flux (Anderson, Joller, and Kuchroo 2016). LAG-3 is expressed on 
activated CD4+ and CD8+ T-cells, as well as on certain NK cell subsets. As LAG-3 affects 
the function of CD8+ T-cells and NK cells that typically do not interact with MHC-II 
molecules, investigations regarding an alternative ligand for LAG-3 has been proposed. In 
this regard, a member of the DC-SIGN family of molecules LSECtin, has been found to be 
another ligand for LAG-3. LSECtin is expressed on several tumors as well as in the liver, 
thereby offering a potential mechanism by which CD8+ T-cells and NK cells expressing 
LAG-3 can be modulated in these tissues (Anderson, Joller, and Kuchroo 2016). Although 
the downstream signaling pathway is still not understood entirely, the unique cytoplasmic 
tail of LAG-3 has three regions that have been shown to be conserved between mice and 
humans. The primary region has a serine phosphorylation portion, the second region has a 
unique KIEELE motif and the third region has glutamic acid-proline (EP) repeats. Out of 
these three, the KIEELE motif has been found to be necessary for the inhibitory function of 
LAG-3 (Anderson, Joller, and Kuchroo 2016). In autoimmunity, LAG-3 functions to 
suppress T-helper cell responses via direct engagement of MHC-II (Anderson, Joller, and 
Kuchroo 2016). Inhibition via the KIEELE motif of LAG-3 acts by mediating cell growth, 
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that is by transmitting anti-proliferative signals to effector cells. The mechanisms by which 
LAG-3 controls extrinsic T-cell regulation is still under investigation. Studies have shown 
LAG-3 signaling to be necessary for effector cell suppression proposing that it may stimulate 
expression of regulatory cytokines or cell surface molecules (Huang et al. 2004). Although 
LAG-3 does not hinder with MHC:CD4 interaction (despite its stronger affinity), studies 
suggest LAG-3 to interfere with TCR signaling and suppress optimal T-cell activation 
(Huang et al. 2004). LAG-3 binding to MHC-II molecules stimulates an immunoreceptor 
tyrosine-based activation motif-mediated inhibitory signaling pathway (Zhao, Liao, and 
Kang 2017). Huang et. al (2004) have shown that ectopic expression of LAG-3 (but not a 
dysfunctional mutant) on CD4+ T-cells is enough to provide regulatory activity that is 
contact-dependent as determined by transwell experiments. Ectopic LAG-3 expression on T-
cells has been found to remarkably decrease proliferative capacity and interestingly, the 
suppressive ability of LAG-3 was similar compared to parallel experiments of ectopically 
expressed Foxp3 (Huang et al. 2004). However, there has been speculation by some 
immunologists that LAG-3 is important for Treg-mediated suppressive function at only 
increased effector T-cell/Treg rations, but unessential at decreased ratios, an idea that 
requires further investigation. Currently, LAG-3 has been identified as a key immune 
regulator in chronic viral infection, parasitic infection, cancer and autoimmunity (Zhao, Liao, 
and Kang 2017).  
 
 
1.4.4.4 Dysfunctional Treg Suppression in T1D 
 
 
Studies of Tregs in T1D mouse models demonstrate a two-step hypothesis in the 
progression of disease from insulitis to overt diabetes. At the first step, autoreactive T-cells 
start homing to the islets but are still kept in check by Tregs. At the second step however, 
islet inflammation (insulitis) progresses to destructive insulitis leading to diabetes 
development as Tregs become dysfunctional and lose their ability to suppress effector T cells 
(Visperas and Vignali 2016b). 
 
 
In human T1D patients, the frequency of Tregs in peripheral blood has been reported 
to be normal. However, a dysfunctional Treg phenoytope and suppressive function has been 
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observed (Visperas and Vignali 2016b). Due to the challenge present in not being able to 
obtain pancreas samples from T1D patients, the majority of studies done in humans have 
been done with peripheral blood cells. Thus, whether Tregs have a key role in controlling β-
cell killing or present a modified phenotypic function within the islets during disease 
progression is unknown. For this reason, mouse models of T1D have been used widely to 
study disease progression (Visperas and Vignali 2016b). 
 
 
In various autoimmune disorders including neuroinflammatory conditions, Tregs have 
defective expression of CTLA-4 and CD25 markers, while other studies have shown reduced 
expression of Foxp3 and IL-10 (Shevach 2018). A subset of Tregs that do not express Foxp3 
but still have suppressive function via other mechanisms, known as Tr1 cells have been 
described (Zeng et al. 2015). Furthermore, studies have shown that specific deletions of 
CTLA-4 from Tregs accelerate development of autoimmune disease which coincided with 
several early observations showing Treg suppressive function can be reversed in vitro and in 
vivo by administering anti-CTLA-4 (Shevach 2018). Similarly, PD-1 expression on Tregs 
have also been shown to be important for their suppressive function, as PD-1+ Tregs have 
been shown to display stronger suppression during chronic viral infections (Francisco et. al 
2010). A study suggested deletion of either PD-1 or its ligand can cause breakdown of 
immune tolerance and subsequently, autoimmunity (Francisco et al. 2010). LAG-3 has been 
shown to play a crucial role for maximal Treg suppression as well and blockade of LAG-3 
on Tregs abolishes their suppressive function. However, investigations on contribution of 
LAG-3 in Treg suppression is controversial as some studies suggest perhaps LAG-3 is 
important for Treg suppressive function at high T-effector/Treg ratios but not so essential at 
reduced ratios (Zhao, Liao, and Kang 2017). Tr1 cells were found to express LAG-3, which 
also play a role in Tr1 induction (Zeng et al. 2015). In addition to LAG-3, Tr1 cells express 
other checkpoint inhibitory molecules following activation such as PD-1 and CTLA-4 (Zeng 
et al. 2015). 
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1.4.5 DC therapies in T1D 
 
 
 
DCs play a key role in both central and peripheral tolerance in T1D by rendering 
autoreactive immune cells anergic and by inducing Tregs, thereby making DCs extremely 
useful for therapeutic interventions. There have been three main DC therapy approaches 
currently employed in autoimmune diseases, 1) adoptive transfer of particular DC subsets, 
2) using DCs to expand Tregs in vitro, and 3) targeting DC subsets in vivo, such as by 
targeting CD11b cDC or CD8 cDC using anti-CD205 antibodies, coupled to specific antigens 
in the absence of inflammatory stimuli leading to Treg generation (Penelope A. Morel 2013). 
The stage of maturity of DCs vastly influences their impact on the immune response. For 
instance, DCs at an immature or semi-mature stage are considered to be useful tools in 
tolerance induction in terms of autoimmunity. Overall, the role of these DCs is to induce 
Treg expansion or immune cells, such as Tr1 cells, with other regulatory mechanisms (Morel 
2013). 
 
 
 
1.4.5.1 Harnessing tolerogenic DCs to improve Treg function 
 
 
 
The generation of tolerogenic DCs with an immature phenotype has proved to be a 
useful tool for therapeutic purposes, as they act as key regulators of the immune response 
and therefore can target Tregs at many checkpoints (Funda et al. 2019). A single injection of 
2 x106 tolerogenic DCs postponed the onset of T1D and resulted in the expansion of splenic 
Tregs in NOD mice. When these cells were injected weekly between ages 8-12 weeks NOD 
mice, they prevented diabetes onset that could be explained by increased IL-7 expression, a 
survival cytokine for Tregs (Funda et al. 2019). 
 
 
Bone-marrow derived DCs from NOD mice have been shown to have a 
hyperinflammatory phenotype consisting of increased NF-kB expression, IL-12 production 
and decreased capacity to induce expansion of Tregs (Morel 2013b). Yet, despite these DC 
defects, several tolerogenic DC protocols implemented in NOD mice have been successful 
in yielding completely functional tolerogenic DCs, showing that NOD mice indeed prove to 
be a suitable model for testing tolerogenic DCs prior to clinical implementation. These 
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tolerogenic DCs possess the ability to prevent T1D or even reverse hyperglycemia in recently 
diagnosed diabetes recipients, (Morel 2013b). 
 
 
Tolerogenic DCs can induce T-cell tolerance via various mechanisms. Presenting self-
antigens by immature DCs to T-cells in the draining lymph node can suppress T-cells to self-
antigens. DCs can drive Treg expansion depending on their environmental signals. For 
instance, mature DCs have been detected in peyer’s patches and the lungs that release 
increased IL-10 but not IL-12, thereby driving IL-10+ producing Treg generation. In 
addition, the antigenic dose, DC maturation, lineage and cytokine milieu are all factors that 
can influence DCs tolerogenic properties and their ability to induce T-cell tolerance (Rutella, 
Danese, and Leone 2006). In T1D, a significant accumulation of ex-vivo expanded DCs has 
been shown in the pancreatic lymph nodes (PLNs) after I.V or I.P administration. DCs tissue 
homing is important as therapeutic DCs have enhanced access to pertinent antigens and they 
can directly dampen the activity of islet-derived immunogenic DC. Furthermore, lymph node 
homing signals such as CCR7 and L-selectin can be overexpressed to achieve greater 
accumulation of tolerogenic DCs (Kalantari et al. 2011). 
 
 
DCs have the potential to expand Tregs in vitro, that when adoptively transferred into 
autoimmune patients, possess the ability to limit the inflammatory response and disease 
development (Kalantari et al. 2011). One study showed that Tregs expanded from islet-
specific TCR transgenic NOD mice (BDC2.5 mouse model) with DCs pulsed with antigenic 
peptide and IL-2, could prevent diabetes in prediabetic NOD mice (Morel 2013b). 
Furthermore, DCs expressing greater levels of CD86 co-stimulatory molecules were more 
competent at expanding Tregs (Morel 2013b). In the presence of GM-CSF, the CD11b cDC 
subset was also shown to stimulate Tregs to proliferate (Morel 2013b). 
 
 
DCs cultured in the presence of certain cytokines such as TSLP or GM-CSF can be 
differentiated towards tolerogenic DCs. For instance, GM-CSF has been shown to induce 
semi-mature, reduced IL-12 producing DCs that express increased levels of MHC-II and co-
stimulatory molecules (Morel 2013b). Thymic stromal lymphopoietin (TSLP) treated DCs 
has also been shown to express high levels of co-stimulatory molecules and MHC-II but 
secrete insignificant levels of IL-12p70. Under these conditions, CD4+CD25-thymocytes are 
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readily converted into CD4+CD25+FoxP3+ Tregs (Morel 2013b). DCs cultured with GM-
CSF and TSLP can lead to a strong expansion of naïve CD4+ T-cells and induce CCL22 and 
CCL17 chemokines, both causing generation of CCR4-expressing Th2 cells (Bell et al. 
2013). An induction of Th2 type response plays a key role in clinical immunotherapeutic 
vaccines. After DC maturation, various cytokines including GM-CSF and TSLP can activate 
the transcription factor STAT5 (Bell et al. 2013). STAT5 consists of two related proteins – 
STAT5A and STAT5B. STAT5A mainly interacts with genes playing a role in 
mammopoiesis and neural function, whereas STAT5B defects have been shown to play a 
crucial role in immune cell functions including impaired T-cell activation, proliferation, 
impaired IL-2 signaling, consequently leading to reduced Tregs and its suppressive function 
(Kanai et. al 2014). In NOD mice, DC defect results partly from a flaw in the JAK-STAT5 
signaling pathway that is related to the idd4 susceptibility gene. The role of STAT5B in 
tolerogenic DCs is not well understood, therefore our group generated transgenic mice 
carrying constitutively active STAT5B signaling under control of the CD11c promoter 
(NODSTAT5B+ mice), in order to abolish the defects of this signaling pathway in NOD 
mice, and to better understand its functions (Zerif et al. 2017). 
 
 
1.4.5.2 Evidence of protection from T1D of transgenic NOD.STAT5B+ mice 
 
 
NODSTAT5B+ transgenic mice were first confirmed for expression of the active form 
of STAT5B in DCs compared to NOD mice (Fig.1) (Zerif et al. 2017). Mice with intact 
STAT5B+ gene were found to be protected 100% from diabetes, compared to NOD mice 
(Fig. 2) (Zerif et al. 2017). This protection from diabetes of NODSTAT5B+ mice was 
associated with increased percentage of Tregs and their enhanced suppressive function of 
highly diabetogenic 8.3-CD8+ T-cells, compared to the suppressive function of Tregs from 
NOD mice (Fig. 3 and 4) (Zerif et al. 2017). 
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Figure 1. Increased expression of the active form of STAT5B in 
DCs of NODSTAT5B+ mice. Permission obtained from 
Elsevier. Licence # 4694861140435. Oct 23, 2019. (Zerif et al. 
2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2. All NODSTAT5B+ are protected from T1D compared 
to NOD mice.  
Permission obtained from Elsevier. Licence # 4694861140435.  
Oct 23, 2019. (Zerif et al. 2017). 
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Figure 3. Increased percentage of Tregs in NODSTAT5B+ mice 
compared to NOD mice. Right: cumulative flow cytometry 
profiles of Tregs (%). Permission obtained from Elsevier. Licence 
# 4694861140435. Oct 23, 2019. (Zerif et al. 2017). 
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Figure 4. NODSTAT5B+ mice Tregs exhibit enhanced 
suppressive function compared to NOD mice Tregs. Permission 
obtained from Elsevier. Licence # 4694861140435. Oct 23, 
2019. (Zerif et al. 2017). 
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            1.4.6 Project Rationale 
 
 
 STAT5B gene defects have been implicated in various immune cell dysfunctions. As 
IL-2RA and Foxp3 are directly regulated by the STAT5B gene, defects namely in T-cell 
activation, proliferation and ultimately function have been reported. Defective Foxp3 
transcription arising from STAT5B gene defects negatively affects Treg number, stability 
and function (Kanai et. al 2014). In addition, STAT5B deficient patients are observed to 
have reduced natural killer cells. STAT5B is highly implicated in regulating genes crucial 
to IgE production, such as DOCK8. DOCK8 gene regulated by STAT5B is also crucial 
in maintaining peripheral CD8+ survival and function, in mice and humans. Importantly, 
STAT5B is associated to T-cell specific functions (T-cell survival, activation, 
proliferation and function, including Treg development and suppressive functions) 
(Kanai et. al 2014). From studies on mice deficient in STAT5, impairment in proliferation 
and/or survival of mast cells, myeloid cells, NK cells and B cells was also reported (Zerif 
et. al 2017). Mice expressing STAT5B constitutively active form that is specific to T- 
and B- cell compartments showed a significant increase in Treg numbers (Zerif et. al 
2017). Although the role of STAT5B is well established in T-cells and other immune 
cells, little was known of the role of STAT5B in tolerogenic DCs. NOD mice carry 
dysfunctional DCs partly due to a defect in the JAK-STAT5 signaling pathway. 
Therefore, our group generated NOD.CD11c.STAT5B+ (NODSTAT5B+) transgenic 
mice that express the STAT5B gene constitutively active under control of the CD11c 
promoter (Zerif et al. 2017). Our findings were the first to report that DCs harboring 
restored STAT5B function re-established DC tolerogenic functions, and these DCs re-
educated Tregs to sustain long-term immune tolerance and T1D protection (Zerif et. al 
2017). Our work continues to investigate Tregs from NODSTAT5B+ mice, that have a 
superior suppressive function, specifically by studying the role of checkpoint inhibitory 
molecules in this protected mouse model. 
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2. Working Hypothesis 
 
 
 
The checkpoint inhibitory molecules PD-1, CTLA-4 and LAG-3 expressed on Tregs of 
 
NODSTAT5B+ mice are of a hierarchical  importance in optimal Treg suppression  in 
 
protection against T1D. 
 
 
 
 
 
 
 
 
 
 
3. Objectives 
 
 
 
Objective #1: Determine the impact of LAG-3 deficiency on diabetes induction in NOD 
and NODSTAT5B+ mice 
 
Objective #2: Determine the profile and function of CD4+ and CD8+ T-cells educated in 
the presence of DCs expressing active STAT5B-CA in the absence of LAG-3 
 
Objective #3: Investigate the expression of checkpoint inhibitory molecules associated 
with diabetes development in NOD and NODSTAT5BLag3-/- mice 
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4. Materials and Methods 
 
 
 
 
4.1 Generation of NOD.STAT5B mice and monitoring diabetes 
 
 
NOD mice were obtained from the Jackson Laboratory (Bar Harbor, ME). 
NOD.CD11c.STAT5B-CA (NODSTAT5B+) mice were generated in our laboratory as 
described (Zerif et al. 2017). Stat5b-CA cDNA was acquired from pMX-puro-Stat5b-CA, 
as a gift from Dr. T Kitamura from the University of Tokyo, Japan. Stat5b-CA cDNA was 
subcloned into the pMYc-pIRES2-EGFP (Clontech Laboratories Inc., Mountain View, CA) 
to produce the Stat5b-CA-IRES2-EGFP construct. This construct was then subcloned into 
a vector harbouring the CD11c promoter (pCD11c), a gift from Dr. K Karjalainen from 
Nanyang Technological University, Singapore. Finally, the transgene DNA sequence 
pCD11c-Stat5b-CA-IRES2-EGFP was split from the vector, purified, sequenced and used 
to produce the transgenic NOD mice at the JDRF Center of Immunological Tolerance in 
T1D facilities (Harvard Medical School, Boston, MA). NOD.Lag3-/- mice were obtained 
from Dr. Vignali and were crossed with NOD.STAT5B+ mice. The offsprings were 
screened for STAT5B+ and LAG-3 expression. The mice screened positive for STAT5B 
and heterozygotes for LAG-3 (LAG-3+/-) were intercrossed to obtain NODSTAT5B+Lag3-
/-. STAT5B and LAG-3 genes were screened by PCR. Mice were monitored for diabetes 
using Uristix urine glucose test (Bayer, Minneapolis, MN). NOD, NODSTAT5B+ and 
NODSTAT5B+Lag3-/- mice used to characterize checkpoint inhibitory molecule 
expression and induction at pre-diabetic stage, i.e between 5 - 9 weeks old. 
 
 
 
 
 
4.2 Antibodies and flow cytometry 
 
 
 
Mouse antibodies against, PE-CF594 anti-CD4 (clone RM4-5) was from BD 
Biosciences (Mountain View, CA). PE-Cy7 anti-CD25 (clone PC61.5), Percp-Cy5.5 anti-
CD3 (clone 145-2C11), Percp-Cy5.5 anti-CD8 (clone 53-6.7), PE anti-PD-1 (clone RMP1-
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30), PE anti- CTLA-4 (clone UC10-4B9), PE anti- LAG-3 (clone C9B7W), PE anti-CD62L 
(clone MEL-14), and FITC anti-Foxp3 (clone FJK-16s) were from eBioscience (San Diego, 
CA). Splenocytes were used to make single cell suspensions for flow cytometry staining. 
For extracellular staining, splenocytes were stained at 4 degrees for 30 minutes and 
subsequently washed for intracellular staining steps. For intracellular staining, splenocytes 
were fixed and permeabilized with Foxp3 staining kit (eBioscience). Splenocytes (5 x 10
5
 
cells per well) were left unstimulated or stimulated with anti-CD3 mAbs (5 μg/ml) for 1 or 
3 days. Cells were harvested and stained with similar markers as day 0 and acquired on the 
Beckman Cytoflex (B53000) and analyzed using the CytExpert software (Beckman 
Coulter). 
 
 
 
 
4.3 Proliferation Assay 
 
 
Splenic CD4+ and CD8+ T-cells (5 x 10
5
 cells per well) from NOD, NODSTAT5B+ 
and NODSTAT5B+Lag3-/- were purified using Ab-coated magnetic beads commercial kit 
(Miltenyi Biotec, San Diego, CA). T-cells were incubated with anti-CD3 (5 μg/ml) and anti-
CD28 (clone 37.51) (2 μg/ml) mAbs for 3 days at 37 °C. T-cells were pulsed with [3H] 
thymidine (1 μCi/well) during the last 18 h of culture, harvested and radioactivity (CPM) 
was determined using scintillation beta-counter. 
 
 
 
4.4 Statistical Analysis 
 
 
  
The results were analyzed using the GraphPad Prism 6.0 software (GraphPad, San 
Diego, CA) and are shown as the mean ± SEM. One-way ANOVA or two-way ANOVA 
tests were used to calculate P values. p ≤ 0.05 were determined to be significant. 
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5. Results 
 
 
 
5.1 Loss of LAG-3 restores diabetes onset in NODSTAT5B+ mice 
 
 
Workman et al. (2005) demonstrated the importance of LAG-3 in maximal Treg 
suppressive function, both in vitro and in vivo. Their work reported that LAG-3 knockout 
mice display overt autoimmunity as observed in Foxp3 knockout or scurfy mice and that 
LAG-3 plays also an important role in regulating cellular homeostasis. In the first set of 
experiments we followed diabetes incidence in NOD mice that are competent or deficient 
in LAG-3. We found no significant difference in diabetes incidence between NOD.Lag3+/-
, NOD.Lag3-/- and NOD mice and that diabetes onset was accelerated by 2 and 3 weeks in 
NOD.Lag3+/- and NOD.Lag3-/- respectively (Fig 5B). These data are in agreement with 
data showing acceleration of diabetes in NOD mice in the absence of LAG-3 (Bettini et. al 
2011). To investigate the contribution of LAG-3 in diabetes protection in our 
NODSTAT5B+ mice model, we monitored diabetes in NODSTAT5B+, 
NODSTAT5B+Lag3+/- and NODSTAT5B+Lag3-/- mice. As we previously reported (Zerif 
et al. 2017), NODSTAT5B+ mice were fully protected from diabetes (Fig 5b). However, 
45% of NODSTAT5B+Lag3-/- and 20% of NODSTAT5B+Lag3+/- mice became diabetic 
(Fig 5b). Together, our data suggest that LAG-3 plays an important role not only in delaying 
but also in protecting from diabetes onset and that other checkpoint inhibitory molecules 
may also play a greater role in controlling disease development and progression.  
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. NODSTAT5B+ and NOD mice monitored for diabetes development upon  
being made heterozygotes or complete knockouts for LAG-3. Mice were monitored for 
diabetes up to 50 weeks of age (n=42). 
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5.2 T-cells of NODSTAT5B+Lag-3-/- mice exhibit high proliferative          
response 
 
The study by (Workman et al. 2005) showed a role for LAG-3 in controlling T-cell 
homeostasis, by a mechanism that could be dependent as well as independent of 
CD4+CD25+ Tregs suppressive cells. It was demonstrated that absence of LAG-3 on T-
cells leads to the dysregulation of T-cells, specifically in their ability to control the 
homeostasis of other leukocyte cells, suggesting that LAG-3 acts as a molecular break to 
regulate cellular proliferation. To determine whether T cells have a higher proliferation rate 
in the absence of LAG-3, CD4+ and CD8+ T cells from NODSTAT5B+ and 
NODSTAT5B+Lag3-/- mice were activated in the presence of anti-CD3 and anti-CD28 
and their level of proliferation was measured. Results showed that, CD4+ and CD8+ T-
cells of NODSTAT5B+ mice proliferated less than those of NOD mice. Importantly, CD4+ 
and CD8+ T-cells of NODSTAT5B+Lag3-/- mice exhibit higher proliferation than T-cells 
of NOD and NODSTAT5B+ mice (Fig. 6). These results suggest, that in the absence of 
LAG-3, CD4+ and CD8+ T cells of NODSTAT5B+ proliferate more vigorously than in 
the presence of LAG-3. 
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. NODSTAT5B+ mice exhibit increased CD8+ T-cell and CD4+ T-cell 
proliferation in the absence of LAG-3; (A) CD8+ T-cells and (B) CD4+ T-cells were 
purified from splenocytes of NOD, NODSTAT5B+ and NODSTAT5BLAG3-/- mice and 
incubated with anti-CD3 and anti-CD28 mAbs. Their levels of proliferation was 
determined using 3H incorporation assay. Data is represented as the average of two 
independent experiments (N=2) 
 
 
 
 
 
 
5.3 Partial restoration of Treg pool in NODSTAT5B+Lag3-/-mice. 
 
 
We used flow cytometry to determine the proportions of CD4+, CD8+ and Treg cell 
 
populations among splenocytes of NODSTAT5B+, NOD and NODSTAT5B+Lag3-/- 
 
mice. We didn’t find a significant difference in the percentage of CD4+ T  
 
cells in NODSTAT5B+ mice as compared to CD4+ T cell in NOD and 
NODSTAT5B+Lag3-/- mice (Fig. 7a). As we previously reported (Zerif et al 2017), the 
percentage of CD8+ T cells in NODSTAT5B+ mice was significantly lower than the 
percentage of CD8+ T cells in NOD mice (Fig. 7B) but returns to a similar CD8+ T-cell 
percentage as NOD mice when NODSTAT5B+ mice are deficient in LAG-3. Analysis of 
Treg cell percentages (a subpopulation of CD4+ T-cells, gated on 
CD3+CD4+CD25+Foxp3+ cells) showed significantly higher percentages in 
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NODSTAT5B+ protected mice compared to NOD and NODSTAT5B+Lag3-/- mice (Fig. 
7C). 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.  
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Figure 7. NODSTAT5B+ mice have increased Treg percentages compared to NOD and  
NODSTAT5B+Lag3-/- mice. Spleen Cells were prepared from NOD, NODSTAT5B+, and 
NODSTAT5B+Lag3-/- mice, stained with anti-CD4, anti-CD8, anti- CD25 and anti-FoxP3 
mAbs and analyzed by FACS. (N=3). Data is represented as mean  SEM (N=3) * p ≤ 
0.05, ** p ≤ 0.01 *** p ≤ 0.001**** p ≤ 0.0001 
 
 
 
 
 
5.4 PD-1, CTLA-4 and LAG-3 expression levels in inactivated Tregs of 
NOD, NODSTAT5B+ and NODSTAT5B+Lag3-/- mice 
 
 
First, we analyzed PD-1, CTLA-4 and LAG-3 expression on Tregs and non-Tregs in 
our three mouse models prior to activation (Fig. 8). Although we expected diabetes-
protected NODSTAT5B+ mice to have significantly increased basal expression of 
the three checkpoint inhibitory molecules on their Tregs 
compared to NOD and NODSTAT5B+Lag3-/- mice, we found an increasing trend in 
percentages of CTLA-4 and LAG-3 expressing Tregs in NODSTAT5B+ mice 
compared to NOD and NODSTAT5B+Lag3-/- mice. Percentage of PD-1 expressing 
Tregs is comparable between NODSTAT5B+, NOD and NODSTAT5B+Lag3-/- 
mice and is higher than percentages of CTLA-4 or LAG-3 expressing Tregs. 
Interestingly, PD-1 and LAG-3, but not CTLA-4 expression on non-Tregs 
(CD4+CD25-Foxp3- cells) in NODSTAT5B+ mice are significantly higher 
compared to NOD mice. 
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Figure 8. No significant differences in basal PD-1, CTLA-4 and LAG-3 expression on  
Tregs in NODSTAT5B+ mice. Splenocytes of the three lines of mice were prepared and 
stained, with anti-CD4, anti-CD25, and anti-Foxp3 mAbs in combination anti-PD1, anti-
CTLA-4 or anti-LAG-3 mAb and analyzed by FACS. Data is represented as mean  SEM 
(N=3) * p ≤ 0.05, ** p ≤ 0.01. 
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5.5 CTLA-4 expression is substantially upregulated on Tregs upon 
activation in NODSTAT5B+ mice 
 
 
As seen in the previous section, basal levels of CTLA-4 and LAG-3 on Tregs 
and non-Tregs were minimal in all three mouse models. However, upon activation 
CTLA-4 and LAG-3 expression is upregulated on Tregs and non-Tregs. PD-1, 
CTLA-4 and LAG-3 expressions in NODSTAT5B+ mice compared to NOD and 
NODSTAT5B+Lag3-/- mice were analyzed following splenocyte activation in vitro 
with anti-CD3 mAb. Overall PD-1 basal expression which was the highest amongst 
the other checkpoint inhibitory molecules unexpectedly decreased in all three mouse 
models following activation (Fig. 9). On the contrary, CTLA-4 and LAG-3 
expression significantly increased upon activation. On Tregs, although an increasing 
trend is observed in LAG-3 expression in NODSTAT5B+ mice compared to NOD 
mice, CTLA-4 increase is observed to be the most significant following activation 
(Fig. 9). Interestingly, PD-1 expression on non-Tregs is transiently increased in 
NODSTAT5B+ mice at day 1 following activation. By day 3, PD-1 expressions on 
non-Tregs returns to basal level in all three strains of mice. We found also that the 
basal level of LAG-3 expression is significantly higher in NODSTAT5B+ mice 
compared to NOD mice on non-Tregs and by day 3 of activation is reduced to resting 
levels. On the contrary, CTLA-4 expression follows an increased trend by day 3 in 
NODSTAT5B+ mice compared to NOD and NODSTAT5B+Lag3-/- mice on non-
Tregs. 
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Figure 9. CTLA-4 is significantly upregulated on Tregs following activation in  
NODSTAT5B+ mice. Splenocytes of the three lines of mice were prepared, then activated 
with anti-CD3 mAb for days 1 and 3, and then stained, with anti-CD4, anti-CD25, and 
anti-Foxp3 mAbs in combination anti-PD1, anti-CTLA-4 or anti-LAG-3 mAbs and 
analyzed by FACS. Data is represented as mean  SEM (N=3) * p ≤ 0.05, ** p ≤ 0.01 *** 
p ≤ 0.001**** p ≤ 0.0001. 
 
 
 
 
D
a
y
 0
D
a
y
 1
D
a
y
 3
0
1 0
2 0
3 0
4 0
N O D
N O D .S T A T 5 B +
N O D .S T A T 5 B + L a g 3 -/-
*
*
L
a
g
-3
+
 T
r
e
g
s
 (
%
)
D
A
Y
 0
D
A
Y
 1
D
A
Y
 3
0
2
4
6 ***
** ***
L
a
g
-3
+
 N
o
n
-T
r
e
g
s
 (
%
)
47 
 
 
5.6 Lowered trend in expression of CD62L on Tregs and non-Tregs in 
NODSTAT5B+ mice 
 
 
CD62L, also known as L-selectin, marks naïve T-cells and is downregulated from the 
 
cell membrane after T-cell activation (Yang et al. 2011). We assessed the expression of 
 
CD62L on Tregs and non-Tregs of NODSTAT5B+ mice compared to NOD and 
 
NODSTAT5B+Lag3-/- mice before activation as well as on days 1 and 3 following anti-CD3 
 
activation. We found that CD62L expression on Tregs and non-Tregs of NODSTAT5B+ 
 
mice were significantly lowered compared to NOD and NODSTAT5B+Lag3-/- mice (Fig. 
 
10). Following activation, CD62L expression remained low on Tregs and was diminished in 
 
non-Tregs of NODSTAT5B+ mice compared to NOD and NODSTAT5B+Lag3-/- mice. 
 
CD62L expression was much more diminished in non-Tregs than Tregs on all strains of mice. 
 
Since optimal Treg activation requires IL-2 (and not only anti-CD3), we expected non-Tregs 
 
will be more activated than Tregs following this manner of activation, consistent with our 
 
findings regarding the degree of CD62L downregulation on non-Tregs compared with Tregs. 
 
 
A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Lowered basal CD62L expression on Tregs and non-Tregs in NODSTAT5B+  
mice. Splenocytes of the three lines of mice were prepared, then activated with anti-CD3 
mAb for days 1 and 3, and then stained, with anti-CD4, anti-CD25, and anti-Foxp3 mAbs 
in combination anti-CD62L mAb. Data was analyzed by FACS. Data is represented as 
mean  SEM (N=3) * p ≤ 0.05, ** p ≤ 0.01. 
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6. Discussion 
 
We previously demonstrated that NODSTAT5B+ mice have a greater pool of Tregs 
with enhanced suppressive function and are 100% protected from T1D as compared to NOD 
mice (Zerif et al.2017). However, when LAG-3 is deleted from these mice, they indeed 
become diabetic (Fig. 5A). Not all NODSTAT5B+Lag3-/- mice become diabetic, in fact, 
only approximately half of the mice develop disease. This raises the question whether other 
checkpoint inhibitory molecules may be of greater importance in conferring optimal Treg 
suppression and diabetes protection. Although several checkpoint inhibitory molecules have 
been described, PD-1, CTLA-4 and LAG-3 were our prime focus, as these molecules are 
found to be important in controlling autoimmunity. Prior to studying these molecules in vitro 
by creating knockout mice as was done in the case of NODSTAT5B+Lag3-/- mice, we first 
characterized the expression of PD-1, CTLA-4 and LAG-3 in our three mouse models (NOD, 
NODSTAT5B+ and NODSTAT5B+Lag3-/- mice). Pre-diabetic mice ranging 5 – 9 weeks 
old were used to determine any differences in the expression of the checkpoint inhibitory 
molecules. We hypothesized that the expression of these checkpoint inhibitory markers will 
be differentially expressed during the early phase of islet inflammation and a hierarchical 
importance of these three checkpoint inhibitory molecules could compromise Treg 
suppressive function during progression of islet inflammation and disease onset. 
 
 
FACS analysis showed no significant differences of CD4+ T-cells in NODSTAT5B+ 
mice versus NOD and NODSTAT5B+Lag3-/- mice. However, percentage of CD8+ T-cells 
was lowered in NODSTAT5B+ mice, suggesting reduced effector T-cell presence and 
activity in young diabetes resistant NODSTAT5B+ mice compared to pre-diabetic NOD 
mice. CD8+ T-cells are widely known as the key drivers of T1D and cause continual islet 
inflammation (Tsai, Shameli, and Santamaria 2008). Indeed, CD8+ effector T cells are 
among the first T cells that home early on to the pancreatic islets and exert their cytotoxic 
function against beta cell using Fas/FasL and preforin (Amrani et al. 1999). Therefore, 
reduced CD8+ effector T cells in young NODSTAT5B+ mice could be also another 
important mechanism by which DCs expressing the active form of STAT5B induce early 
immune tolerance in NODSTAT5B+ mice. Interestingly, the CD8+ T cell pool seem to 
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increase in NODSTAT5B+Lag3-/- mice, although not significantly compared to 
NODSTAT5B+ mice (Fig. 7). These data are in agreement with previous reports showing 
that, in the absence of LAG-3, CD4+ and CD8+ T-cells undergo hyperproliferation 
(Workman et al. 2005) which we too observed when CD8+ T-cells are activated in vitro (Fig. 
6). Moreover, NODSTAT5B+Lag3-/- mice have a reduced Treg pool compared to 
NODSTAT5B+ mice (Fig. 7) suggesting that even though these mice undergo CD4+ and 
CD8+ T-cell hyperproliferation, they are not endowed with anti-inflammatory or suppressive 
function. These cells may account for a more hyperinflammatory T cell lineage. One way 
this can be confirmed is by studying the phenotype of these cells, specifically, transcription 
factors and cytokine gene expression by qPCR in terms of Th1/Th2 cell bias. For instance, 
studying the expression of the transcription factors T-bet and Gata-3, that are responsible for 
CD4+ T-cell differentiation towards Th1 or Th2 cells respectively, can provide insight in the 
fate of CD4+ T-cells in our NODSTAT5B+Lag3-/- mouse model. 
 
 
NODSTAT5B+ mice were found to have increased Treg pool compared to both NOD 
and NODSTAT5B+Lag3-/- mice. The Treg pool was significantly decreased in 
NODSTAT5B+Lag3-/- mice, but never reaches the low level of the Treg pool observed in 
the case of NOD mice. Interestingly, the Treg pool in NODSTAT5B+Lag3-/- mice remains 
significantly higher than the Treg pool in NOD mice. There may be two explanations to 
account for these results. First, mice used in these experiments were at a pre-diabetic stage 
and do not yet have a massive islet inflammation that could affect the Treg pool. This 
hypothesis is corroborated by previous studies showing a reduction of the Treg pool during 
islet inflammation and diabetes progression in NOD mice (D’Alise et al. 2008). Second, only 
approximately 50% of NODSTAT5B+Lag3-/- mice become diabetic, suggesting that the 
Treg pool in NODSTAT5BLag-3-/- mice is not enough to provide a full protection from 
diabetes in the absence of the Lag-3 gene. As Tregs are generally known to be functionally 
unstable in T1D (and other autoimmune diseases), we also expect that not only their 
frequency, but also their functionality might be compromised in the case of 
NODSTAT5B+Lag3-/- mice. This possibility is under investigation. 
 
After we confirmed that NODSTAT5B+ mice have increased Treg numbers 
compared to NOD and NODSTAT5B+Lag3-/- mice, we investigated whether the expression 
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of PD-1, CTLA-4 and LAG-3 checkpoint inhibitory molecules, known to be expressed on 
Tregs for their maximal suppressive function, are important in diabetes protection in 
NODSTAT5B+ mice. The first step to doing this involved determining the percentage of 
checkpoint inhibitory molecule expression on Tregs of protected NODSTAT5B+ mice 
compared to NOD and NODSTAT5B+Lag3-/- mice. These molecules have been studied 
widely in cancer therapy, however their contribution to immune tolerance in T1D is not fully 
understood. Our data show that PD-1 expression on Tregs is similar, between 
NODSTAT5B+, NOD and NODSTAT5B+Lag3-/- mice. Interestingly, PD-1 expression on 
non-Tregs (CD4+ T cells) is significantly higher in NODSTAT5B+ mice compared to NOD 
mice, but not NODSTAT5B+Lag3-/- mice. Furthermore, basal expression of CTLA-4 and 
LAG-3 on Tregs of all three mice, including diabetes protected NODSTAT5B+ mice, were 
lower than expected, since these molecules are normally highly expressed on Tregs of wild 
type mice (Gianchecchi and Fierabracci 2018b). We observe an increasing trend in Lag-3 
expression on Tregs in NODSTAT5B+ mice compared to NOD mice. Interestingly, similar 
to PD-1 expression on non-Tregs, we found significantly higher LAG-3 expression on non 
Tregs of NODSTAT5B+ mice compared to NOD mice. Overall basal CTLA-4 expression 
however, was found to be the lowest among the three checkpoint inhibitory molecules. One 
study by (Lundholm et al. 2006) investigated the role of CTLA-4 in diabetes protection in 
the NOD mouse model. They examined CTLA-4 expression in splenic CD4+ T-cells of 
NOD and B6 mice before and after anti-CD3 stimulation in vitro. Prior to stimulation, 
CTLA-4 expression was very minimal, similar to our findings and upon anti-CD3 
stimulation, CD4+ T-cells of B6 wild type mice express significantly higher levels of CTLA-
4 than NOD mice. This led us to determine the expression of checkpoint inhibitory molecules 
PD-1, LAG-3 and CTLA-4 upon anti-CD3 stimulation of splenic cells of our three strains of 
mice. Similar to Lundholm et al. (2006), we also found that upon anti-CD3 activation, the 
expression of CTLA-4 and LAG-3 on Tregs is increased compared to basal levels in all three 
mouse models. CTLA-4 and LAG-3 were also transiently increased on non-Tregs. 
Unexpectedly, PD-1 expression decreases on Tregs after activation, with a decreasing trend 
observed in NODSTAT5B+ mice compared to NOD and NODSTAT5B+Lag3-/- mice. On 
the contrary, PD-1 expression is significantly increased in NODSTAT5B+ mice on non-
Tregs early on following activation compared to NOD mice. A similar trend is observed with 
LAG-3 expression on non-Tregs of NODSTAT5B+ mice. The most significant inhibitory 
checkpoint molecule increase we observed after anti-CD3 stimulation is CTLA-4, which is 
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much more upregulated on Tregs, but not on non Tregs, of NODSTAT5B+ mice compared 
to both NOD and NODSTAT5B+Lag3-/- mice. Characterization of these molecules after 
activation yielded two interesting suggestions: first, CTLA-4 expression on Tregs seems to 
be hierarchically more important for optimal Treg suppressive function at least in vitro (a 
speculation that needs to be further confirmed by Treg suppressive functional assays using 
neutralizing antibodies against PD-1, CTLA-4 and LAG-3), and secondly, PD-1 and LAG-
3 expression on non-Tregs of NODSTAT5B+ mice might play a role in suppression or 
protection against disease, independently of Tregs. In agreement with this explanation, non-
Tregs expressing PD-1 and LAG-3 were also found to prevent autoimmune disease such as 
colitis (White and Wraith 2016). 
 
One report by (Wing et al. 2008) clearly demonstrated the crucial importance of 
CTLA-4 expression on Tregs to exert their optimal suppressive function. They showed that 
CTLA-4 specific deletion on Tregs causes spontaneous disease development namely, 
systemic lymphoproliferation, lethal T-cell mediated autoimmunity and IgE 
hyperproduction. Moreover, CTLA-4 deletion on Tregs was shown to severely hinder in vivo 
and in vitro Treg suppression, specifically through downregulation of B7-1/2 expression on 
DCs. These data suggest that Tregs can no longer maintain self-tolerance if CTLA-4-
mediated Treg suppression is impaired, and that this breakdown of Treg induced immune 
tolerance cannot be rescued by other mechanisms of suppression. Another article (Zhang et 
al. 2016) reported that mice that are engineered to have partial FoxP3 deficiency and PD-1 
deficiency developed early-onset lymphoproliferation and fatal autoimmune pancreatitis. 
However, when T-cells containing adequate FoxP3 were transferred to these mice, despite 
of whether these cells were from WT or PD-1 defective mice, they rescued their autoimmune 
condition. These findings suggest that Tregs mainly protect against onset of spontaneous 
autoimmunity independently of PD-1 expression. However, partial Foxp3 deficiency 
combined with PD-1 deletion was catastrophic, as this combination led to proliferation of 
effector and memory T-cells, a pro-inflammatory profile that led to tissue specific 
autoimmunity. These data suggest that Foxp3 and PD-1 work together, via independent 
pathways to maintain immune homeostasis. PD-1 was found specifically to regulate the 
balance between effector and regulatory T-cells, and activation signals, while FoxP3 is 
enough for leading regulation via maintaining Treg integrity and function. Similarly, recent 
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studies suggest blockade of PD-1 signaling in murine Tregs, render Tregs to be more 
immunosuppressive and exhibit greater proliferation (Kamada et al. 2019). Taken together, 
these articles provide insight on why CTLA-4 expression versus PD-1 may be of more 
importance to Treg function. In the NODSTAT5B+ mouse model, the role of CTLA-4 and 
PD-1 in diabetes protection needs to be confirmed using suppressive function experiments 
both in vitro and in vivo. Other than the possibility of CTLA-4 being simply more crucial for 
Treg suppressive function than PD-1, another explanation may be that these two molecules 
function to provide suppression at different phases of autoimmune tolerance. Thus, CTLA-4 
has been labelled as the “principal” immune checkpoint inhibitor as it has been shown to halt 
autoreactive T-cells at the early phase during naïve T-cell activation, which usually occurs 
in draining lymph nodes. On the contrary, the PD-1 pathway modulates already activated T-
cells typically later on during an peripheral immune response (Buchbinder and Desai 2016). 
These findings provide another possible explanation as to why CTLA-4 but not PD-1 is the 
most significantly upregulated in NODSTAT5B+ mice compared to young pre-diabetic 
NOD and NODSTAT5B+Lag3-/- mice. 
 
Another study (Zhang et al. 2017) reported that mice lacking LAG-3 expression on 
Tregs were less prone to become diabetic and that protection from diabetes in this mouse 
model is dependent on increased Treg proliferation but not their suppressive function. 
Analysis of Lag-3 deficient Tregs did not show greater suppressive function as compared to 
Lag-3-competent Tregs. Instead, they exhibit increased proliferation and survival benefit that 
over time, offers a greater suppressive capability. As opposed to this model, NOD.Lag-3-/-
mice in which LAG-3 deletion affect all T-cell subsets develop accelerated diabetes (Bettini, 
et. al 2011). These findings mirror our observations in NODSTAT5B+Lag3-/- mice which 
is an overall knockout model, where nearly 50% of these mice become diabetic. Therefore, 
it is of importance to understand whether NODSTAT5B+Lag3-/- mice are partially protected 
due to some compensation mechanism in Treg cell frequency itself. It is likely that diabetes 
onset in 50% of NODSTAT5B+Lag-3-/- mice might be the result of increased proliferation 
of pathogenic T-cell subsets. However, the other 50% of NODSTAT5B+Lag3-/- mice not 
developing diabetes may be the result of increased proliferation of tolerogenic T-cell subsets 
(Tregs, Tr1 cells). Our data show a slightly increasing trend of LAG-3 in NODSTAT5B+ 
mice compared to NOD mice on Tregs, although not significantly. Whether more LAG-3 
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increases significantly on Tregs in NODSTAT5B+ older mice needs investigation. In 
addition, performing in vitro and in vivo Treg suppressive function experiments will clarify 
the importance LAG-3 (compared to CTLA-4 and PD-1) in suppression of autoimmune 
diabetes in NODSTAT5B+ mice. 
 
 
Our data showed also that PD-1 is significantly upregulated on non-Tregs 
(CD4+CD25-Foxp3-T cells) in NODSTAT5B+ mice compared to NOD mice. A similar 
trend is observed in LAG-3 expression on non-Tregs. What is the significance of PD-1, 
CTLA-4 and LAG-3 expression on non-Treg subsets? A recent study (Dong et al. 2019) 
demonstrated a significant positive correlation in PD-1 and LAG-3 expression with liver 
inflammation in hepatitis B-virus patients. CD4+ T-cells of these patients have increased 
PD-1 and LAG-3 levels, and fail to produce IFN-γ, IL-2 and TNF-α cytokines, suggesting 
that CD4+ T cells are more exhausted. Additionally, PD-1 and LAG-3 blockade rescued the 
ability of CD4+ T-cells to proliferate and to secrete cytokines. These studies suggest that in 
our diabetes protected NODSTAT5B+ model, increased PD-1 and LAG-3 expression in the 
CD4+ T-cell subsets (non-tregs) may be of a more exhausted phenotype and therefore less 
pathogenic in nature. Another possible explanation of these molecules expressed on non-
Tregs may be that these cells are a type of cells called “Tr1 regulatory cells.” Tr1 cells are 
highly implicated in autoimmunity and are characterized by a lack of Foxp3 and CD25 
expression (Zeng et al. 2015). Indeed, PD-1, CTLA-4 and LAG-3 are expressed on these 
suppressive cell subsets (Zeng et al. 2015). One of many mechanisms by which Tr1 cells 
exert their suppression is via expression of these checkpoint inhibitory molecules, a 
suppressive mechanism similar to Tregs. Further investigation into the phenotype and 
possible suppressive capacity of the non-Tregs in our experiments is required. 
 
 
CD62L (L-selectin) is a key T-cell homing receptor and a T-cell development marker. 
Naïve T-cells are high in CD62L expression and upon ligand binding (peripheral node 
addressin or PNAd), T-cells are able to enter lymph nodes through high endothelial venules 
(Yang et. al 2011). In NODSTAT5B+ mice Tregs exhibit significantly lowered basal CD62L 
expression, and a similar decreasing trend is observed after activation, compared to NOD 
and NODSTAT5B+Lag3-/- mice (Fig. 10). This suggests Tregs are more active in our 
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protected mice model NODSTAT5B+ compared to pre-diabetic mice. We observe a similar 
trend in non-Tregs of NODSTAT5B+ protected mice as well, which may imply greater 
activity of the more tolerogenic subsets within this population, such as the Tr1 type lineage. 
As mentioned, further investigation is required to determine the nature of the Tr1 cells in our 
mouse models. The expression of the characteristic cell-surface molecules of Tr1 cells can 
be further validated using flow cytometry, as Tr1 cells are CD4+ CD49b+ LAG-3+ CD226+ 
(Zeng et al. 2015).  Another way to distinguish Tr1 cells among the overall CD4+ T-cell 
population is by their unique cytokine profile. Tr1 cells are IL-10 high, TGF-β+ IFN-γ+ IL-
5+ IL-4− and IL-2 low/negative (Zeng et al. 2015). Additionally, these cells can be purified 
by FACS (Fluorescence-activated cell sorting) using their characteristic cell-surface 
molecule expression, to be used for suppressive functional assays in order to determine 
whether these cells have suppressive capacity, and to what extent. 
 
Another important aspect to consider is since the percentage of expression of 
checkpoint inhibitory molecules in our experiments were measured one- and three-days post 
activation only, we must note that they may be upregulated more significantly at certain 
timepoints specifically. For instance, if we were to extend our timepoints further, we may 
observe an increase in PD-1 expression (compared to CTLA-4) in our protected 
NODSTAT5B+ mice compared to pre-diabetic mice, namely since as mentioned, PD-1 acts 
at a later stage of a peripheral immune response. Therefore, to account for this, we must 
increase timepoints at which we look at the expression of PD-1, CTLA-4 and LAG-3 in-
vitro. In addition, NODSTAT5B+ mice and pre-diabetic mice must also be sacrificed at 
various timepoints as disease itself progresses, to classify which checkpoint inhibitory 
molecule is crucial at which disease stage. Overall, this will give us a better idea as to exactly 
which stage Tregs and non-Tregs utilize specific checkpoint inhibitory molecules to suppress 
autoreactive cells. 
 
 
 
 
 
 
55 
 
7. Conclusion 
 
Our data shows that NODSTAT5B+ mice are 100% protected from T1D, have 
increased Treg frequencies that are CD62L low, suggesting that Tregs are more active in 
protected mice compared to pre-diabetic NOD and NODSTAT5B+Lag3-/- mice. CTLA-4 
expression on Tregs is significantly upregulated in NODSTAT5B+ mice following 
activation suggesting this molecule is of crucial importance in conferring optimal Treg 
suppression at least during the initial phases of diabetes. Although characterization gives us 
a good idea of the importance of CTLA-4 in optimal Treg suppression, further experiments 
namely Treg functional assays need to be performed to confirm this in vitro and in vivo. 
NODSTAT5B+ mice can be administered neutralizing antibodies to PD-1 and/or CTLA-4 
to provide insight on the importance of these molecules in diabetes initiation and 
progression. Additionally, suppressive functional assays can be performed in-vitro using 
Tregs and non-Tregs from these mice. Tregs and non-Tregs can be co-cultured with peptide-
pulsed irradiated APCs from NOD mice, and highly diabetogenic 8.3-CD8+ T-cells (TCR 
transgenic mice) at various ratios to determine 8.3- CD8-T-cell proliferation, as done in our 
previous studies (Zerif et al. 2017). The major limitation is whether this hierarchical 
importance of checkpoint inhibitory molecules investigated through our mouse models can 
be ultimately translated to human therapies. 
 
 
Ultimately, the objective of this research is to educate Tregs in T1D patients to 
acquire enhanced suppressive function in order to halt disease development. As disease 
progresses, Treg integrity breaks down, and modulating key pathways including those of the 
checkpoint inhibitory pathways can play a major role in rescuing optimal Treg suppressive 
function. Characterization of these molecules using autoimmune diabetic murine models 
provides us with a great tool to study this in depth - including the stage of disease at which 
these molecules function to inhibit effector T cells, and the hierarchical importance of each 
of these molecules to modify the ones most effective at preventing disease initiation and 
progression. 
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